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ABSTRACT 
Developing New Strategies for Engineering Novel Natural Product Metabolic Pathways 
Caroline Anne Patenode 
Natural products represent a large and diverse array of molecules. Natural products and 
their derivatives play important roles in the human sphere, serving as pharmaceuticals, 
biofuels, and more. However, the structural complexity of many promising natural 
products prohibits industrial production sufficient to make full use of their capabilities. 
The challenge posed by natural products has spurred many advances in multiple fields. 
Despite these achievements, ignorance of the native metabolic pathways and 
inefficiencies in manipulating the genes involved has slowed the ability of science to 
capitalize on the enormous potential of natural products. 
In Chapter 1, we begin by surveying the fields concerned with the production or 
variation of natural products. This begins with organic synthesis, continues with in vivo 
and in vitro biocatalytic methods, and concludes with the “combination” techniques that 
seek to unite the strengths of biocatalysis and organic chemistry: precursor-driven 
biosynthesis, mutasynthesis and semi-synthesis.   
After examining the advantages and disadvantages of the extant technologies, in 
Chapter 2 we describe a novel strategy to develop semi-synthetic routes to 
underexplored classes of natural products. While it employs features of existing 
techniques, our strategy originates from a fundamentally different conception of natural 
product production, which looks away from the native precursors of a single target, and 
towards versatile precursors amenable to multiple forms of chemical modification. We 
then carry out a demonstration of this strategy by first biosynthetically producing 2Z,7E-
farnesol from heterologously expressed Mycobacterium tuberculosis synthetases, and 
subsequently derivatizing this unnatural precursor into a set of novel Ambrox© analogs. 
Complex biocatalytic applications rely on DNA manipulation technologies to 
rapidly construct and diversify metabolic pathways. When components of the targeted 
pathway are unknown or poorly understood, the creation of large libraries of variant 
pathways can be employed to circumvent these limitations and rapidly develop the 
desired phenotype. In Chapter 3, we harness our existing library building technology, 
Reiterative Recombination, to the yeast sexual reproduction cycle for the purpose of 
combining separately constructed library strains via simple mating and chromosome 
segregation into an exponentially larger combinatorial library. This chapter describes the 
design, construction, and initial validation of this system, termed Reiterative Segregation.   
 Finally, in Chapter 4, we explore possible elaborations of the Reiterative 
Segregation design, and work towards combining libraries of alternative sugar metabolic 
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1.0 Chapter Outlook 
Natural products comprise a diverse range of chemical compounds produced by living 
organisms1. While humans have used natural products for millennia as medicine, 
perfumes, and dyes, it is only since Friedrich Wöhler successfully synthesized urea2 in 
1828 that scientists have explored synthetic sources for these products, and the possibility 
of creating unnatural derivatives with their own properties. This paradigm shift heralded 
wave after wave of new methods in chemistry, biology, and integrated techniques for 
making natural products and derivatives thereof. Today, natural products and their 
derivatives are a key part of activities encompassing the pharmaceutical industry,3,4  the 
biofuel industry,5,6,7 and many more8. 
The role of natural products in the pharmaceutical industry is particularly well 
documented: between 1981 and 2010, 64% of the New Chemical Entities (NCEs) were 
natural products or inspired by a natural product9. Many pharmaceuticals are unaltered 
natural products, such as penicillin V. Many others are synthetic structures related to 
various natural products. Having been preselected by nature for bioactivity, specificity 
and affinity, natural products may be viewed as “privileged scaffolds” for further drug 
optimization10. Natural product inspired structures are particularly well represented in 
anti-cancer drugs and antibiotics9, owing to the stupendous diversity of chemicals created 
in many organisms for self-defense.  While the pharmaceutical industry had begun to turn 
away from NP libraries due to the difficulty of production, the mixed success of 
combinatorial chemistry11,12 and concurrent advancements in NP production techniques 
have rekindled interest in small, focused libraries based on NP structures13. 
	   3	  
A newer arena for natural products is the growing biofuel industry. The desperate 
need for non-petrochemical alternative fuels has stimulated the development of 
bioproduction of ethanol, and 1,4-butanediol. Other natural products are valuable tools 
for selection, probes, and stimulators in the laboratory, advancing the bounds of chemical 
and molecular biology13. The efficient production of secondary metabolites in particular 
has been a source of many new insights in biology. Dismissed as waste products for 
decades, new roles for secondary metabolites in sophisticated intercellular and 
interorganismal communication, energy storage, and self-defense are discovered every 
year, thanks to increased availability of these substrates1.  
Ever since Wöhler’s groundbreaking achievement, the techniques used to produce 
natural products and their derivatives have evolved dramatically, drawing inspiration 
from multiple fields. We will address the major methodologies below, in three sections. 
First, we will give a broad overview of organic chemistry’s place in natural product 
synthesis. Second, we will discuss biocatalysis in greater detail, including combinatorial 
biosynthesis, metabolic engineering, and in vitro biocatalysis. Finally, we will discuss 
semi-synthesis and precursor-driven biosynthesis, two approaches that combine aspects 
of both chemistry and biology. Special attention will be given to the penicillin family, a 
class of natural products in the unique position of having had significant interactions with 
each of the methodologies above. 
1. 1 Organic Synthesis 
Natural product production has been linked to organic chemistry since its inception. In 
the nineteenth century, the chemical synthesis of a natural product and subsequent 
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comparison of degradation products was the best way to confirm its structure13. Organic 
synthesis was also used industrially to make early pharmaceuticals such as aspirin. 
Aspirin can be viewed as an early natural product derivative; salicylic acid is a natural 
product derived from willow bark that has been used as medicine for pain and 
inflammation since ancient Egypt. In 1853, Charles Gerhardt synthesized a derivative, 
acetylsalicylic acid15, which had fewer side effects and became the dominant 
pharmaceutical.  
Other natural products such as penicillin highlighted the limits of organic 
synthesis in this period. Despite a massive effort during World War II (involving almost 
1,000 chemists on two continents) to develop a synthetic route to penicillin (Demain), it 
wasn’t successfully synthesized until 195716.  In the interim, the biosynthetic and semi-
synthetic production routes had firmly established themselves as an attractive alternative 
to chemical synthesis17.  
The development of spectrometric methods14 to determine molecular structures 
had an enormous impact on natural product chemical synthesis. These techniques 
provided a quicker way to determine the structures of natural products, and allowed 
retrosynthetic chemistry and synthetic strategy to permeate the field. New types of 
reactions relevant to natural product structures were developed in the latter half of the 
twentieth century, such as asymmetric catalysis18 and metal salts-based C-H and C-C 
bond activations19,20. These exciting developments challenged chemists to synthesize 
increasingly complex natural products.  
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Perhaps the crowning achievement21 of this period of chemical synthesis is the 
synthesis of palytoxin, a massive natural product isolated from seaweed, containing a 
staggering 64 stereocenters22. This synthesis demonstrated that any complex natural 
product structure could be reached by organic synthesis, albeit often in low yields.  
The standard bearer for the power of chemistry to achieve industrial-scale 
synthesis of complex natural products is (-)discodermalide. This polyketide was isolated 
from a deep-sea sponge Discodermia dissoluta in 1990. Its strong antitumor activity 
generated a lot of interest from the pharmaceutical industry, but as discodermolide only 
made up 0.002% of the dried weight of the sponge, another production route was required 
before any further testing. Schreiber and coworkers took on the challenge, and completed 
a total synthesis in 199323. Based on this and works from Smith24 and Paterson25, 
Novartis developed a scaled up synthesis of discodermalide in 2004, creating 60g in a 39-
step synthesis, and demonstrating the full potential of industrial synthetic chemistry26 
Given these incredible advances in the chemistry toolkit, focus in the modern era 
has shifted from achieving the targets per se to rethinking the tenets of synthetic design. 
Efficiency, cost, environmental concerns and scalability are more important than ever27. 
In consequence, debate has sprung up about the role of organic synthesis in natural 
product synthesis28. The significant improvement of biology-based techniques that began 
with penicillin has led many to question whether total organic synthesis of huge 
molecules such as palytoxin served any purpose other than to demonstrate the skill of the 
laboratory involved.  
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Many defend the development of synthetic routes to these “challenge” molecules 
as learning tools. For example, the total organic synthesis of the insecticide azadirachtin 
by Stephen Ley’s group took 22 years and requires 64 transformations29. The intent was 
not to provide a source of azadirachtin;  its extraction from the seeds of the Indian neem 
tree can be done in a matter of hours30. Total synthesis of natural products often provide 
insight into the reactions occurring in the natural biosynthetic pathway, and the challenge 
of synthesizing a highly complex molecule often inspired new reagents and 
strategies22,28,29 Ley and others argue that this information gained in the development of 
novel synthetic routes justifies the effort28.  
Developing a totally synthetic route to a compound with potentially important 
properties naturally also creates a number of intermediate structures that may contain key 
structural elements that impart the valuable biological activity. These intermediates 
inform studies of the biological mechanism and create a simpler and more scalable target 
molecule. One powerful example of this added benefit of total synthesis is the anticancer 
drug eribulin, a potent non-taxane microtubule inhibitor.  Eribulin was first made as an 
intermediate in the synthesis of halochondrin B, a macrolide isolated from marine sponge 
that showed promising anticancer activity in tissue culture screening. While the total 
synthesis of halochondrin B was achieved in 199231, it was too complex to develop for 
industry. However, the intermediates already synthesized were readily available for 
evaluation, which led to the identification of eribulin32. 
At the same time, new conceptions of synthetic strategy have emerged. As part of 
the work to keep organic synthesis highly relevant, much emphasis has been placed on 
conservation tactics in synthesis design27. Traditional synthesis relied heavily on 
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laborious protecting-group strategies that lowered efficiencies and created a large amount 
of molecular waste. The biosynthetically-inspired concepts of economy of steps, atoms, 
and redox reactions33 are important factors. Atom conservation (in which ideally, 
reactants only contain those atoms which will become part of the final molecule, as in 
multicomponent reactions) reduces waste, and therefore expense. Redox conservation (in 
which the oxidation state of the reactants is only altered in one direction) tends to reduce 
the number of steps by minimizing the need for refunctionalization of functional groups. 
The development of protecting-group-free syntheses greatly serves all three economies. 
In contrast, if we re-examine the synthesis of palytoxin the inefficiency is clear: of the 39 
steps in the synthesis, 13 steps are for managing protecting groups, 15 steps are for 
refunctionalization, and only 11 steps contribute to skeleton formation22.  
Several new chemical methods have in alignment with these goals have become 
very useful for scaling up natural product related chemistry. The metal salt C-C and C-H 
reactions were effective, but used up equimolar amounts of the expensive metal reagents. 
The transition to metallic catalysts made such reactions much more practicable19,34. 
These direct activations also give the syntheses more step economy; compare DuBois’ 
32-step synthesis of (-)-tetrodotoxin employing direct C-H functionalization35 with Isobe 
and coworker’s 67-step synthesis which did not36.  
Cascade reactions, also known as domino or tandem reactions, and one-pot 
procedures can make use of unstable but helpful intermediates without having to isolate 
them. The product of one reaction serves as the substrate of the next reaction, creating a 
choreographed sequence of steps towards the final product37. One example of this type of 
reaction is the synthesis of the sesquiterpene (−)-aromadendranediol by the MacMillan 
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group38 from achiral commercial starting materials. This synthesis combined a transition-
metal catalysis with an ‘organocascade’ in a dual catalyst system, in which each cycle of 
the cascade is mediated by a unique chiral catalyst, improving selectivity and expanding 
the array of possible chemical transformations. New peptide catalysts have also been 
used to improve specificity39,40. 
Several philosophies of natural product analog design have emerged that rely 
heavily on the increasing sophistication of synthetic transformations. Combinatorial 
chemistry, in which a set of related substrates is reacted en masse to form a set of related 
products11, has greatly accelerated chemical synthesis, leading to the rapid creation of 
large chemical libraries to be used in conjunction with high-throughput screening. 
However, libraries based on biologically active structures have been far more successful 
than truly random libraries, emphasizing the importance of natural product inspiration. 
The Danishefsky laboratory has pioneered diverted total synthesis, in which fragments 
of a complex molecule are made separately and then joined together41. As with precursor-
driven biosynthesis (see section 1.1.3), this allows specific, deep-seated structural 
modifications to take place without disturbing other parts of the molecule by modifying a 
core fragments separately.  Stuart Schreiber has pioneered diversity-oriented synthesis, 
in which intermediates in synthetic pathway are examined as the starting point for new 
transformation toward related products42. This reflects the biological reality, in which 
many diverse molecules are made from the same starting materials, eg IPP and DMAPP 
giving rise to the entire terpene family. Biologically-oriented synthesis takes complex 
biologically active compounds and breaks them down into simpler and simpler structures 
to identify key structural elements to be used as pharmaceutical scaffolds. This goal is 
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very similar to function-oriented synthesis which also attempts to develop simper 
analogs of active molecules43. Others have developed hybrid molecules, in which 
different parts of a molecule perform different functions, analogous to multiple functional 
domains present on a single protein44 .  
Natural products have served as challenge and inspiration to organic synthesis for 
over a century. Advances in organic synthesis are also reflected in methods such as 
precursor-driven biosynthesis and semi-synthesis that incorporate synthesis steps. While 
the major focus of the field may have shifted away from purely virtuoso synthetic 
achievements, the achievements in reaction development and design, and the concurrent 
facilitation of combination methods, indicate that synthetic chemistry will remain 
significant source of natural product production for the foreseeable future.  
1.2 Biocatalysis 
1.2.1 Cellular biosynthesis 
By definition, all natural products are originally derived via biosynthesis, and ancient 
production methods for natural products such as ethanol, relied exclusively on native 
biosynthesis. Prior to advent of precise DNA manipulation techniques, the ability to 
optimize natural product production was very limited.  
One of the great biosynthetic success stories of this period is the production of 
penicillin. Fleming’s original strain of Penicillium notatum45 produced such low amounts 
of penicillin that it took over a year to produce enough material for clinical testing46.  
Once its antibiotic properties were proven however, the demand created by WWII 
sparked a steady stream of advances over the next few decades. Optimization of 
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fermentation media alone improved production from a strain of Penicillium chrysogenum 
100-fold47. The birth of fed-batch fermentation augmented yields even further48. Brute-
force strain improvement techniques were then employed in the early 1950s, in which 
higher-producing strains were bombarded with X-rays and later UV rays to create 
random mutations, creating isolates reaching yields as high as 1.8 mg/mL49. However, it 
was not until the biosynthetic pathway could be specifically augmented by DNA 
manipulation that truly impressive product yields were observed50,51.  
Facile manipulation of DNA is the foundation upon which all modern biocatalysis 
stands52. The ability to chemically synthesize DNA with high accuracy at unprecedented 
scale has impacted every area of biology. Whole genes can be synthesized with precise 
mutations, host-specific regulatory regions and codon usage, thus improving 
heterologous expression of proteins. Improved assembly and construction techniques 
such as DNA Assembler53, Gibson Assembly54, and delitto perfetto55 speed biosynthetic 
pathway and gene circuit construction both inside and outside the chromosome. 
Technologies such as MAGE56 and CRISPR57,58 facilitate multiple rapid changes across 
genomes. (DNA assembly technologies are discussed further in Chapter III.) Rapid 
genome sequencing and the precise monitoring of cellular expression level by RNA 
probes paved the way for “omics” fields The synthesis of oligo libraries plays a key role 
in directed evolution. Every biologically-based field or technique has been profoundly 
impacted by the use of precise and reliable DNA manipulation techniques.  
Heterologous expression of biosynthetic pathways in resilient, well-understood 
and rapidly growing microbial hosts like E. coli or S. cerevisiae is desirable for industrial 
production7,59. However, the proteins of many higher eukaryotic organisms require 
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extensive modifications to be functional.  Identification of the enzymes and substrates 
performing these modifications led to “humanized” yeasts Pichia stipitis and Aspergillus 
niger, able to express correctly glycosylated human proteins 60,61,62. This simplifies 
production of human antibodies, and provides a template for the expression of 
glycosylated enzymes from other biosynthetic pathways.  
Biosynthetic pathways generally require extensive optimization to produce 
significant amounts of the desired natural product. In situations where understanding of 
the pathway is incomplete, the use of combinatorial libraries has proven to be a 
powerful tool63,64. A library is made up of different combinations or variants of 
components of the pathway of interest. The variation may originate from random 
mutations created by error-prone PCR65, global transcription machinery engineering 
(gTME)66, different homologs of a particular enzyme67, and more. Large libraries 
augment biosynthetic production dramatically, and examination of successful members 
can identify possible bottlenecks in the pathway. However, a sufficiently stringent 
selection or high-throughput screening is required to make effective use of a library68,69. 
In well-characterized enzymes in which the biosynthetic pathway has been 
completely elucidated, alterations are greatly informed by the subfield of metabolic 
engineering. One natural product often plays multiple roles in the cell: as a regulatory 
signal, as a precursor to other downstream products, and/or the executor of a more 
specialized function such as self-defense70. Cellular biosynthetic pathways are likewise 
intertwined, and the influence of competing pathways, transcriptional regulations, and 
redox requirements on the yield are often difficult to discern from the pathway itself71. 
Metabolic engineering provides a systems-level approach to creating a particular cell 
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phenotype through reconfiguring many components of metabolic regulation, rather than 
focusing only on the final product-forming reaction72. Understanding how each small 
change will affect the complex metabolic network remains a significant challenge.  
Successful metabolic engineering projects require an adequately elucidated 
metabolic network, the ability to regulate expression of and/or modify the proteins 
involved, and the use of a selection or sufficiently high-throughput screen.  In the twenty-
five years since its inception, metabolic engineering has developed a number of tools to 
address these challenges, and has particularly benefitted from advancements in related 
fields, particularly ‘omics’ technologies and computational systems biology73.  
High-throughput sequencing has provided a wealth of genomic information 
from many species. Genomic techniques have been used to identify potential biosynthetic 
pathways of native natural products. For example, Keasling and coworkers identified the 
cytochrome P450 monooxygenase that performs a three-step oxidation of amorpha-4,11-
diene to artemisinic acid by comparing the genome of native producer Asteraceae. annua 
with other members of the Asteraceae family to identify common sesquiterpene lactone 
biosynthesis enzymes74. Using different methods Hong and coworkers analyzed the 
genome of the bacteria Mannheimia succiniciproducens to predict the enzymes of the 
succinic acid biosynthetic pathway via ORF prediction and homology analysis75. Readily 
available sequencing has also stimulated genome prospecting, in which new natural 
products and the novel biosynthetic enzymes that make them are discovered and added to 
the biosynthetic “toolkit”76. 
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 Other “omics” technologies such as metabolomics77, transcriptomics, proteomics 
via mass spectrometry78, and metabolic flux analysis79 create highly detailed snapshots of 
many aspects of cellular activity at a single-cell level. The ability to track these changes 
under different stimuli creates a living model of the cellular metabolism.   
The staggering amount of data required to accurately define even a portion of a 
cell motivated the development of systems biology analysis80,81. A number of automated 
tools to construct novel pathways and identify likely targets for manipulation via 
engineering or synthetic biology methods have shown promise82,83. In silico models are 
most advanced in existing microbial cell factory organisms like E. coli and S. 
cerevisiae81. This systems-level information will be invaluable when optimizing 
individual production strains for industrial use.  
The increasing technical sophistication of biosynthesis has prompted the field to 
expand beyond natural biosynthetic pathways to combinatorial biosynthesis [Fig1-1]. 
Combinatorial biosynthesis is the construction of new biosynthetic pathways 
incorporating enzymes from multiple biosynthetic pathways or multiple organisms to 
create novel biological products. This subfield emerged in the 1980s, and initially 
focused on the highly modular polyketide synthase (PKS) clusters84. Polyketide synthases 
are encoded as clusters of genes broken into repeating modules. Each module contains a 
ketosynthasedomain, an acyltransferase (AT) domain, and an acyl carrier protein, plus 
one to three additional catalytic domains that process the beta-carbon of the growing 
polyketide. One early success in combinatorial biosynthesis is the diversification of the 6-
deoxyerythronolide B synthase (DEBS) PKS cluster from Streptomyces coelicor, which 
normally produces the macrolide ring of erythromycin. The cluster was modified by the 
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exchange of the DEBS acyltransferase and beta-processing domains for the AT, beta-
carbon reduction, and beta-carbon dehydration domains from the Streptomyces lividans 
rapamycin PKS cluster. Six different substitutions in each of the five DEBS modules 
were made, creating a library of unnatural macrolide products85.
	  
Figure 1-1 : Combinatorial Biosynthesis. In combinatorial biosynthesis, enzymes from multiple 
pathways or organisms are assembled to form an unnatural pathway leading to novel products.  
Combinatorial biosynthesis has particularly benefitted from enzyme engineering 
technology86. Previously, structural diversification of the unnatural molecules was limited 
due to the substrate specificity of the enzymes involved. Directed evolution, targeted 
mutation, and the creation of chimeric enzymes have all served to broaden substrate 
specificity, thus promoting novel biosynthetic products87. Enzyme engineering is further 
discussed in section 1.2.2. While PKSs and non-ribosomal peptide synthetases (NRPSs) 
are still major areas of interest in combinatorial biotechnology, other classes of molecules 
such as terpenoids88 and alkaloids89 have also been successfully produced by 
combinatorial biotechnology.  
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Advancements in biosynthesis are reflected in all methods of natural product 
production incorporating biological elements. In vitro biocatalysis, precursor-driven 
biosynthesis, and semi-synthesis have all benefitted from the achievements and 
innovations of biosynthesis, and biosynthesis has likewise incorporated information 
derived from these related fields.  
1.2.2 In Vitro Biocatalysis 
Enzymes are attractive catalysts in many ways. Nature has created a diverse array of 
these biological catalysts to address every type of biological chemistry. Enzymes are able 
to promote a wide range of efficient, selective, and enantio- and regiospecific reactions 
under mild conditions90.  As a result of these properties, in vitro biocatalysis [Fig1-2] also 
has a much smaller ecological footprint than traditional chemical synthesis. Purified 
enzymes have been used industrially in vitro as biocatalysts for decades, in applications 
as diverse as medical diagnostics, biofuel production, and cleaning supplies86 .  
An early industrial example still in use today is the generation of 6-
aminopenicillanic acid (6-APA), the core molecule of the penicillin family. 6-APA is 
diversified by semi-synthesis into a wide range of antibiotics including ampicillin and 
amoxicillin51. However, 6-APA is not a natural intermediate, as the acyl side chain 
addition occurs before the cyclization of the thiazolidine ring17. Instead, 6-APA is 
prepared through in vitro biocatalysis. Penicillin G is biosynthesized, and then the acyl 
side chain is cleaved off by immobilized penicillin G acylase to reveal 6-APA91.   
Biocatalysts’ high selectivity and chiral precision have earned them a growing 
role in the production of natural products and derivatives. Despite these advantages, 
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enzymes as biocatalysts are not as widely used as they could be, due to factors such as 
stability, solubility, and costs associated with expression and purification of the enzymes 
and required factors. There also may not be an existing enzyme suited to every industrial 
task86.  
Enzyme engineering is beginning to address a number of these concerns. While 
it is very valuable to have crystal structures and known catalytic mechanisms of an 
enzyme to focus alterations, improvements in methods of generating large mutant 
libraries and screening procedures have resulted in significant improvements even in less 
well-understood enzymes92. Directed evolution and semi-rational design have been used 
to increase or decrease the substrate specificity of enzymes87,93, improve activity94, 
change an enzyme that usually produces a racemic product into a stereoselective one95  
improve the solubility96 and to develop highly thermostable mutants97.  
As our understanding of biosynthesis grows, the emerging subfield of systems 
biocatalysis becomes increasingly valuable for complex processes. Systems biocatalysis 
is the in vitro organization of enzymes to construct complex reaction cascades for 
efficient syntheses of valuable chemical products. A structural perspective guides the 
choice of precursor, and the selection of each enzyme in the cascade98.  There are clear 
parallels between this strategy and that of retrosynthetic analysis, particularly regarding 
atom and step economy. As in combinatorial biosynthesis, enzymes from different 
pathways and different organisms can be employed in a single artificial synthetic 
pathway.  
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In the last two and a half decades, many systems biocatalysis cascades have 
attained such complexity that they can be viewed as miniature artificial metabolisms 
focused towards a particular product99. One early application reconstituting the yeast 
glycolysis pathway in a cell-free system for ethanol production100. Another early 
achievement solved the difficulty of cofactor utilization by incorporating phosphoenol 
pyruvate as a sacrificial reagent in addition to the substrate to create an elegant closed-
loop recycling of ATP and NAD+ concurrent with sugar synthesis101. 
Moving the biosynthetic process out of the cell and onto a “blank slate” 
significantly reduces the number of variables. When membranes are removed, the 
kinetics of diffusion and membrane transport no longer slow production rates. Likewise, 
it becomes technically simple to supply substrates at high concentration and monitor 
reaction rates.  The absence of any known or unknown regulatory	   proteins eliminates 
most endogenous regulation of enzyme activity. The enzymes in the cascade can also be 
expressed and purified from different organisms, which is particularly valuable for 
eukaryotic enzymes with elaborate modifications. Maintaining a viable cell also imposes 
a number of additional challenges on the production process including narrower ranges of 
pH and temperature, sensitivity to co-solvents, and the potential cellular toxicity of the 
target molecule or intermediate. Cell survival also requires the reaction of interest to 
proceed in or near the same location as the coterminous performance of a complex 
metabolism. Components of the metabolism can potentially divert the substrate or key 
cofactors away from the production reaction, or perform undesired transformations on 
intermediates or the final product. Despite significant improvements in metabolic flux 
simulation and prediction software, it is very difficult to adequately account for the 
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enormous complexity conferred by a living cell, making an in vitro biocatalytic reaction 
relatively simple.  
          
By far, the greatest technical hurdle in the widespread adoption of in vitro 
biocatalysis is the laborious purification of the required enzymes and cofactors.  New 
potential solutions to this problem are developed every day. Mass genome modification 
Figure 1-2: In vitro Biocatalysis. When biocatalysis is carried out in vivo, the other components 
in the cell could potentially interfere with the desired reaction. In contrast, in vitro biocatalysis 
contains only a defined environment.	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techniques such as MAGE and CRISPR facilitate the addition of common affinity tags to 
multiple proteins, allowing components of an entire pathway to be purified at once. The 
dropping cost of gene synthesis also simplifies heterologous expression. An experiment 
with a transketolase derived from the thermophilic bacteria Geobacilus 
stearothermophilus led to a unique one-step purification method that could be expanded 
to other thermophile enzymes. The transketolase was heterologously expressed in E. coli, 
after which the crude extracts were subjected to heat shock at 65°C for 45 minutes, and 
then spun down, recovering the purified protein in similar yields as by affinity 
chromatography102.  
 Advancements in sequencing, purifications, and enzymology are making in vitro 
biocatalysis an increasingly valuable technique in industrial natural product productions. 
Systems biocatalysis promises to redefine in vitro biocatalysis just as cascade chemistry 
and one-pot syntheses redefined organic synthetic strategies. As environmental concerns 
become a higher and higher priority, “white” technologies like biocatalysis are poised to 
become more prominent in both industry and in the laboratory.  
1.3 Combination approaches to natural product synthesis 
1.3.1 Precursor-Driven Biosynthesis and Mutasynthesis 
Precursor-Driven Biosynthesis (PDB) is one of the earliest methods for bringing 
chemistry and biology together for natural product production and diversification. In 
PDB, synthetically produced analogs of a targeted precursor are fed to a cell and 
subsequently transformed by enzymes of the target’s native pathway to create unnatural 
analogs of complex molecules103[Fig1-3].  
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The penicillin family provides an early example of the principles of PDB.  Early 
on, researchers had found that their cultures were producing several different types of 
penicillins, depending on the precise strain, fermentation conditions, and the exact 
fermentation media. The core structure of 6-APA remained the same, but a variety of acyl 
side chains were being incorporated. Researchers found that by feeding specific side 
chain molecules to the production culture they could produce different penicillin analogs 
with different biological behavior. For example, high concentrations of phenylalanine or 
phenylacetic acid in the media would result in the high production of penicillin G, a very 
potent analog, while supplementing the media with phenoxyacetic acid instead resulted in 
penicillin V, an orally active analog104,105.  
Using PDB, an array of simple precursors can thus be synthesized by organic 
chemistry and then be transformed by the host cell to generate many analogs of a 
complex natural product far more quickly than the creation of the whole natural product 
analogs in the test tube. Depending on where the precursor enters the biosynthetic 
pathway, these variants can be incorporated into parts of the final product that are 
difficult to access using other total or semi-synthetic methods103,106. 
Successful PDB restricts the synthetic precursor to 1) molecules that can be taken 
up by the producer organism, 2) structures that can be accepted by the enzymes of 
interest, and 3) molecules that will not prove toxic to the producer organism. It also 
requires that the producer organism can be cultivated, and that at least some knowledge 
of the biosynthetic pathway intermediates and enzymology is known.  
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Figure 1-3: Precursor-Driven Biosynthesis (PDB): The above diagram is taking place in vivo. 
The natural precursor (black, top left corner) is synthesized, and is transformed by each of the 
three central enzymes in turn, to ultimately become part of the complex natural product (black, 
top right corner.) The synthetic precursors (red, lower left corner) were made by organic synthesis 
before being fed to the host cell. The synthetic and the natural precursors are similar enough that 
they are also transformed by the host enzymes and form analogs (lower right corner) of the native 
product. The contents of the top right corner and the bottom right corner are all produced 
concurrently, and are likely to be all extracted together due to their structural similarities. 
PDB is further complicated by the activity of the natural biosynthetic pathway. As 
both the natural and the synthetic precursors are being taken up by the same pathway, the 
desired product is mixed with the natural products. Since these are generally of very 
similar chemical and physical properties, the extraction of the pure product can be very 
difficult. Likewise, the natural precursors compete with the synthetic precursors, so very 
high concentrations of the synthetic molecule are routinely required to achieve significant 
amounts of transformed material.    
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Mutasynthesis advanced from PDB to address the challenges posed by the 
natural pathway. In his 1963 article on the biosynthesis of antibiotics, Birch suggested 
that a host organism could be mutated to no longer produce the normal precursor at all, 
thus facilitating incorporation of the synthetic precursor by removing competition 
between it and the natural precursor107, and the technique was first successfully employed 
by Shier and colleagues in 1969 to create four “hybrimycin” derivatives of neomycin108.  
However, it was not until 1977 that Rinehart coined the term “mutasynthesis” in the 
discussion of his work with aminocyclitol antibiotics109. 
In mutasynthesis, the natural precursor is removed by inactivating the enzyme that 
supplies it [Fig1-4]. Not only does this remove competition for the downstream metabolic 
pathway, it also results in fewer undesired metabolites produced, and thus higher and 
purer yields of the desired product. While mutasynthesis avoids several of the difficulties 
of PDB, it requires greater knowledge of each enzyme and its sequence in order to 
correctly target the key enzyme for inactivation. It also cannot be used on those pathways 
essential to the cell. As with PDB, the uptake, incorporation, toxicity, and expense of the 
mutasynthons frequently pose significant challenges. 
Recent increases in the availability of small molecule libraries, and in the number 
of fully sequenced biosynthetic gene clusters have caused a parallel renaissance in PDB 
and mutasynthesis. Several remarkable example of modern PDB and mutasynthesis 
explore diverse classes of molecules such as non-ribosomal peptides and polyketides, as 
well as the established β-lactams and aminocyclitols and many more110.   
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Weist and coworkers created variations of the glycopeptide antibiotic 
vancomycin111. Vancomycin is one of the few treatments left for methicillin-resistant 
Staphylococcus aureus (MRSA) infections. The discovery of safer and more potent 
variants is desirable, but diversification of glycopeptides, particularly their backbones, by 
chemical synthesis is extremely challenging due to their high structural complexity.  
Using mutasynthesis, Weist et al were able to generate a set of analogs diversified about 
the AB macrocycle, which is a key structural element in its antibiotic activity, setting the 
stage for greater product discovery in this class of molecules. 
	  
Figure 1-4: Mutasynthesis. This strategy is almost identical to that depicted in Figure 1-3, 
except that the native biosynthetic pathway has been blocked by mutation or deletion of 
enzyme(s) that make the native precursor (top left.) The mutation or deletion is represented by 
the red asterix and the absence of the pathway is represented by the gray color. The three central 
host enzymes are still functional, but now they exclusively transform the synthetic precursor 
analogs (red, lower left corner.) As a result, only the non-native analogs of the complex natural 
product are produced.  
*
	   24	  
	  	   While mutasynthesis has obvious value in the exploration of natural product leads 
in drug discovery, only the macrolactone doramectin is routinely made by mutasynthesis 
at the industrial scale112. Streptomyces avermitilis produces a variety of antiparasitic 
avermectins used largely in veterinary care. Doramectin is a derivative produced by 
supplementing a mutated strain S. avermitilis with cyclohexancarbanoic acid. As the 
mutated strain is unable to produce the fatty acid that normally serves as the starting 
block of avermectin, the doramectin is produced cleanly and in high yields. 
The modular nature of polyketide synthase pathways and their frequently 
permissive substrate sites have lent themselves particularly well to PDB and 
mutasynthesis. One example is the development of “rapalogues”, analogs to the 
anticancer agent rapamycin. Previous analogs of rapamycin had already been produced 
by semi-synthesis, but their diversifications were all additions to the starter unit 4,5-
dihydroxycyclohex-1-enecarboxylic acid (DHCHC), that is, the six-membered ring and 
most of its projections were always preserved. Entirely new classes of rapalogues were 
easily made by diversifying the starter unit itself--cyclohexanecarboxylic acid, cyclohex-
1-enecarboxylic acid, cycloheptanecarboxylic acid, norborane carboxylic acid and 
tetrahydro-2H-pyran-4-carboxylic acid were all successfully incorporated110,113. 
Remarkably, even very large mutasynthons have been successfully incorporated by PKS 
enzymes, demonstrating the potential for sophisticated applications of PKS 
pathways114,115.  
Heterologous expression of biosynthetic pathways increases the industrial 
potential of PDB and mutasynthesis. A number of microorganisms, such as E. coli and S. 
cerevisiae, are well understood as cell factories and confer many advantages in terms of 
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cultivation and growth rates. Many tools and techniques developed for these organisms 
are likewise then available to augment production with further metabolic engineering or 
directed evolution116. Moving a biosynthetic pathway to another organism increases the 
risk that the mutasynthon or the final product will be toxic to the host, simply because the 
host doesn’t naturally synthesize similar molecules, but it also circumvents the possibility 
of creating lethal mutations. The Khosla laboratory demonstrated the feasibility and 
potential value of this technique by successfully reconstituting the second half of the 
epothilone biosynthesis pathway from Sorangium cellulosum in E. coli114. In addition to 
the facile creation of epothilone derivatives, this technique could also be viewed as a way 
to simplify biosynthetic production of complex molecules in more tractable hosts by 
supplementing the culture with the normal epothilone precursor (not found in E. coli). 
Subsequent strain improvement and examination of epothilone enzymology was also 
facilitated by expression in E. coli117.   
PDB and mutasynthesis are particularly well-suited to rapid optimization of lead 
structures, as in drug design. They have played an important role in the pharmaceutical 
industry for decades. Recent achievements in screening, metabolic engineering, DNA 
synthesis and organic synthesis have not surpassed PDB and mutasynthesis; instead they 
have strengthened these techniques and facilitated their use in drug design and potentially 
industrial production.  
1.3.2 Semi-Synthesis 
Semi-synthesis refers to the production of a complex molecule in two steps: first, the 
biosynthetic production of a simpler molecule, and second, the subsequent transformation 
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of the biosynthetically produced precursor by organic chemistry [Fig1-5].  Semi-
synthesis has been in use for many years. Penicillin once again provides a classic 
example: In the 1950s, strains of Staphylococcus aureus that were resistant to the original 
penicillins G and V had begun to emerge in hospitals17.  The future of penicillins was 
saved by the subsequent development of potent new semi-synthetic penicillins derived 
from the acylation of the 6-APA core. These synthetic side chains created potent new 
antibiotics with novel activities such as a broader spectrum (amoxicillin), β-lactamase 
resistance (methicillin), or activity against gram-negative bacteria (piperacillin). The 
pharmaceutical industry still makes these alternative penicillins by acylating the 6-APA 
core51.  
 Semi-synthesis, like PDB, aims to combine the strengths of organic chemistry and 
biology to produce complex molecules. In both, the biological aspect of production is 
employed largely to create stereospecificity and complex carbon linkages. The chemical 
aspect is used to create unnatural analogs of the molecule of interest. While PDB’s 
synthetic precursors can create structural variation in the core of the molecule, the 
structural diversity of these precursors is limited to those structures that can be 
recognized and incorporated by the targeted enzymatic pathway. By contrast, in semi-
synthesis, the chemistry is performed after the core of the molecule has been 
biosynthetically produced. While the more complex structure of the precursor may 
sometimes prevent chemical modification at certain sites in the molecule, a greater 
variety of reactions is available.  
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Figure 1-5 : Semi-Synthesis. In semi-synthesis, a precursor molecule is biosynthesized (left), 
and then altered by synthetic chemistry (right, red.) As with PDB, the biological half of the 
production route can take advantage of the specificity and stereoselectivity of biocatalysts, and 
the synthetic half can employ some of the extensive organic synthesis techniques. 
 One demonstration of the potential power of semi-synthesis is the production of 
the anti-cancer agent paclitaxel (Taxol). Paclitaxel is a potent antitumor agent, originally 
isolated in the bark of the Pacific Yew tree. This bark contained such a tiny amount of 
paclitaxel that isolating enough for clinical trials was impractical.  The biosynthetic 
pathway was also unknown at the time. While several synthetic routes were completed, 
the yields remained too low for larger production. Plant cell culture was also attempted 
with some success118, but feedback inhibition and low yields at the bioreactor level 
remained a problem.  Advanced clinical trials were only possible because of a 
semisynthetic route in which an advanced taxoid 10-deacetylbaccatin III was purified 
from the needles of the European Yew tree Taxus baccata119. This was a far more 
available and renewable source than the bark of the Pacific Yew, and could be readily 
transformed into paclitaxel by chemistry.   
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Semi-synthesis is a versatile technique and an excellent alternative to complete 
biosynthesis when downstream enzymes of a biosynthetic pathway are unknown or 
difficult to work with.  
1.4 Conclusion 
Natural products will be required for pharmaceuticals, fuels, and other tools. Despite their 
differences, each of the production methods discussed in this chapter plays an important 
role in the industrial production of natural products. As clearly demonstrated by the 
penicillin family, there are multiple production routes of varying advantage to most 
molecules.  The unsustainable nature of petroleum-based reagents may push organic 
synthesis away from mass production and towards more specialized explorations, such as 
lead optimization for pharmaceuticals. In contrast, the incentivization of 
environmentally-friendly “white” industry techniques could lead to an era where the cell 
is the principle workhorse of natural product synthesis. However, to achieve optimal 
success, each target should be regarded individually, and be accorded a specific approach 
tailored to its structural requirements. 
Despite the remarkable innovations in all fields in the last century, there remain 
many challenges. Improvements in laboratory techniques, and refinements in the 
conception of production design are hardly redundant, and serve in the pursuit of more 
precise and efficient control of production. Creative solutions for natural product 
synthesis ensure that natural products will continue to play a key role in many industries.  
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2.0 Chapter Outlook 
In Chapter 2, we outline and demonstrate a new strategy for the production of natural 
products and unnatural derivatives. This method draws on both biosynthesis and synthetic 
chemistry for the efficient production of tricyclic labdane ethers and hydrobenzofuran 
derivatives allowing access to the fragrance 9-epi-Ambrox1 and a set of novel Ambrox 
analogs.  
As discussed in Chapter 1, natural products and their analogs comprise a vast 
array of classes and structures2. Many of these molecules have been of enormous benefit 
to humanity3-5, in spheres as diverse as antibiotics6-8, antitumoregenics9,10, insecticides11, 
and biofuels12,13. Yet many molecules with valuable properties are not in use, and many 
other potentially impactful molecules have not been tested, due to difficulty or cost of 
production14. Our lab wanted to use our combined expertise in organic chemistry and in 
microbiology to develop a new strategy to for the perennial difficulty of natural product 
production. Specifically, we put forth a structure-oriented strategy that uses 
bioengineering to biosynthesize advanced off-pathway intermediates, which were 
carefully chosen to serve as versatile scaffold molecules for further elaboration by 
synthetic chemistry.  
 We chose to demonstrate this production strategy on the terpene family of secondary 
metabolites. Terpenes are the largest group of natural products, and play highly diverse 
roles both inside and outside the cell, including as membrane components, defense 
against attackers, and messages to conspecifics15. Their roles in many different industries 
have made them very attractive targets for metabolic engineering. We were able to make 
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an E. coli strain that produced Z,E-farnesol, and collected enough pure material to 
successfully carry out some chemical derivitizations.  
2.1 Introduction 
2.1.1 The “jigsaw” strategy of natural product production 
Many exciting new methods have been employed for the production of various terpenoid 
products. One high-profile example from recent years is the production of the potent anti-
malarial drug artemisinin. Artemisinin is a complex sesquiterpene lactone endoperoxide 
natively produced in low amounts by sweet wormwood, Artemisia annua16. Both the 
extraction process and the total synthesis17 were expensive and low-yielding, making it 
an ideal challenge for new technologies.  
The Keasling laboratory answered this challenge with a landmark semi-synthetic 
approach that engineered yeast and later E. coli to produce artemisinic acid, artemisinin’s 
immediate precursor18.  One major difficulty in this work was the synthesis of the 
complex terpene olefin precursor, amorphadiene. Ro and coworkers engineered yeast to 
overproduce a native metabolite, farnesyl pyrophosphate (FPP) to serve as a substrate 
pool. They then introduced the native A. annua amorphadiene synthase. The remaining 
hurdle was the difficult, selective oxidation and reaction of amorphadiene to 
dihydroartemisinic acid. This was surmounted first by introduction of a newly identified 
A. annua P450 enzyme, and later by the engineering of well-characterized promiscuous 
bacterial P450 enzyme, engineered to accept amorphadiene as a substrate19.  
Keasling’s core strategy in this project was to stay close to the natural 
biosynthetic pathway. This strategy is frequently seen in the production of natural 
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products: if the molecule is too complex to be made by total synthesis, and is produced in 
too small quantities in its natural host, elucidation of the natural biosynthetic pathway 
begins. Ideally, the target molecule’s biosynthetic pathway is fully known, and can be 
easily transferred to a model organism for production. However, given the enormous 
diversity of natural products and small-molecule-producing organisms, it is unsurprising 
that one or more enzymes of the pathway of interest may be unknown, or challenging to 
express heterologously. In addition, natural products of interest are frequently toxic to the 
host expression cell.  
At this juncture, the common approach is to proceed backwards along the native 
biosynthetic pathway until an intermediate is found that can be easily produced 
biosynthetically, while retaining enough of the complexity of the final molecule that 
synthetic chemistry modifications remain feasible. The logic of this approach is clear, but 
by remaining tied to the native order of transformations a wealth of synthetic chemistry 
knowledge is passed over. In organic chemistry, a single structure may be reached by 
many different synthetic routes; likewise, the same natural product may be reached by 
different biotransformations in different organisms. For example, both bacteria and yeast 
produce isopentylpyrophosphate (IPP), a key precursor of terpene biosynthesis. However, 
the biosynthetic enzymes that synthesize IPP and the immediate precursors of IPP are 
completely different20. If all biosynthetic molecules are examined on the basis of their 
chemical structure rather than their position in the metabolism, alternate biosynthetic and 
combination routes may be identified.   
Here we put forth a novel combination strategy to leverage the respective strengths of 
bioengineering and organic synthesis for the efficient and sustainable production of 
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complex natural and unnatural organic molecules [Figure 2-1]. Our strategy originates 
from a fundamentally different conception of the development of a semi-synthetic route. 
Rather than using fermentation in heterologous hosts to produce an advanced 
intermediate in a target molecule’s natural biosynthetic pathway and implementing 
subsequent organic transformations to produce the final product, our approach identifies a 
versatile biosynthetic intermediate amenable to relevant chemical modifications. 
Importantly, this does not necessitate that the chosen compounds occur as natural 
intermediates in the target’s biosynthetic pathway. Instead, unrelated precursors, 
synthetic and biosynthetic transformations are pieces assembled to form a coherent 
production route, as with pieces in a jigsaw. By this approach, optimization of 
biosynthetic production of relatively few molecules can result in the efficient semi-
synthetic production of many.  
Traces of this concept have naturally appeared in the vast array of small molecule 
production literature, but to our knowledge it has never been outlined as a separate 
concept. A structurally-oriented approach is clearly demonstrated by Cuevas and 
coworkers in their efforts21 to facilitate the production of Ecteinascidin (ET-743), a 
potent antitumor agent isolated from the marine tunicate Ecteinascidia turbinate22. While 
a total synthesis had already been achieved23, it was insufficient 	  for the requirements of a 
clinical study (0.75% yield). As the biosynthetic pathway was not known, the authors 
were unable to look to the native precursors to develop a semi-synthetic route. Instead, 
they examined the structure in isolation, and compared it with other known molecules. 
By broadening their search away from the native host and closely related species, they 
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identified cyanosafracin B, a natural antibiotic produced by the terrestrial bacterium 
Pseudomonas fluorescens. (Ikeda). Safracin B has a very similar core structure to ET-743 
	  
Figure	   2-­1:	   “Jigsaw”	   strategy	   for	   natural	   product	   production.	   (A)	   Ambrox(2)	   and	   9-­‐epi-­‐
Ambrox(1)	   production	   from	   natural	   products	   derived	   from	   E,E-­‐FOH.	   (B)	   The	   proposed	   “Jigsaw”	  
combination	   strategy	   (C)	   The	   “Jigsaw”	   semi-­‐synthetic	   strategy	   applied	   to	   the	   production	   of	   9-­‐epi-­‐
Ambrox	  and	  novel	  analogs.	  
and can be produced in kilogram quantities from bacterial culture24. Using this cheap, 
abundant precursor, Cuevas and coworkers efficiently synthesized ET-743 and related 
derivatives. Industrial production of ET-743 (under the name Yondelis) still uses this 
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disparate organisms for similar chirality and functionality appears to have been viewed as 
a last resort in the context of the specific problem, and was largely overlooked as a 
general method25.   
Sang Yup Lee’s SymPheny BioPathway Predictor26 software also represents a 
step away from strict adherence to native synthetic pathways. To biosynthesize 1,4-
butanediol (BDO), a valuable commodity chemical that is not naturally produced in any 
organism, Yim and coworkers used extensive computer modeling of the E. coli 
metabolism, known reaction chemistry and enzymes to identify approximately 10,000 
combinatorial biosynthetic pathways that would lead to BDO from any of a set of 
common metabolites. Further advanced software that incorporated group contribution27 
theory and constraint-based modeling28 was used to eliminate pathways with unfavorable 
thermodynamics or poor maximum theoretical yield, respectively. The remaining ~1000 
pathways were further winnowed based on pathway length, number of unknown 
enzymes, and number of non-native steps while maintaining high theoretical BDO yield. 
While several candidates were tested, the final pathway from succinate and alpha-
ketoglutarate to BDO in E. coli consisted of seven  transformations, only two of which 
were native to E. coli. The other five steps were catalyzed by enzymes taken from various 
pathways in Porphyromonas gingivalis, Mycobacterium bovis, and Clostridium 
acetolbutylicum. This approach necessarily requires exploration of non-native pathways 
(even in such cases where the target molecule is a metabolite.) As there is no template, 
the potential precursors are evaluated only according to their structure, and the enzymes 
only as chemical catalysts. However, in addition to being a technically complex and 
expensive program, SymPheny’s work is entirely in vivo and relies on those enzymes that 
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may be correctly expressed in E. coli. The applications of SymPheny have also largely 
remained in the paradigm of a single target development.  
Another factor to consider when choosing a biosynthetic precursor is its flexibility 
in regards to analog creation and chemical ornamentation. Derivatives of natural products 
alone represent a large and growing segment of the pharmaceutical industry14, and have 
high potential in materials science and biofuel development29. Once a relevant structure 
has been discovered, it is advantageous to produce said structure in such a way to 
facilitate derivations at every site. Often, the natural pathway intermediates are assembled 
so that certain parts of the final analog are very difficult to modify. This represents 
another disadvantage of techniques relying heavily on natural biosynthetic pathways, and 
another advantage of our proposed method. 
2.1.2 The semi-synthesis of 9-epi-Ambrox 
Target Selection 
 To demonstrate our “Jigsaw” strategy, we applied it to the synthesis of complex 
terpenes. First, we engineered E. coli to produce the rare compound 2-Z, 6-E-farnesol 
(Z,E-FOH). Then, using chemical synthesis, we converted this versatile precursor to the 
tricyclic labdane ether fragrance 9-epi-Ambrox and several related derivatives.  
Ambergris-type odorants have been a key ingredient in the perfume industry for 
centuries. Ambrox was originally isolated from sperm whale ambergris, where it is made 
from ambrein via photochemistry1. Naturally, this is not an adequate source for such an 
industrially important molecule30, and an alternative route was required. While several 
total syntheses have been accomplished over the years, they have poor enantioselectivity, 
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and mediocre yields31. The industrial source of Ambrox is sclareol, a diterpene diol 
laboriously isolated from Clary sage. The sclareol is then transformed into Ambrox via an 
extended chemical degradation32,33. Recently, Schalk and co-workers achieved sclareol 
production in E. coli, although at insufficient yields for industrial adaptation34.   
Precursor Selection 
We chose 2-Z, 6-E-farnesol (Z,E-FOH) as our biosynthesized precursor for practical as 
well as conceptual reasons. Firstly, it is easily converted into Z,E-homoFOH, and some 
prior examples of the cyclization of homofarnesol to Ambrox isomers made it a safe 
precursor for the chemistry half of the production1,31. Secondly, the stereoselectivity of 
biosynthetic reactions are a powerful incentive for their incorporation into production 
routes, and the 2-Z,6-E faresol stereoisomer is very difficult to obtain synthetically, as 
reflected in its price (~$1000/mg)35. Thirdly, at the time of project development, Z,E-
FOH had never been heterologously expressed in either E. coli adding novelty to our 
design, although another group published on Z,E-FOH production in E. coli during the 
course of our experiments36.  
E. coli production strain design 
E. coli natively synthesizes the all trans (E,E) version of farnesol from all trans 
(E,E) farnesyl-pyrophosphate (E,E-FPP). E,E-FPP is derived from the endogenous 5-
carbon terpene precursors isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). In E. coli, IPP and DMAPP are the products of the 
methylerythritol phosphate (MEP) pathway, also known as the non-mevalonate or 
MEP/DOXP pathway20. Our goal was to produce adequate quantities of Z,E-FOH for 
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further chemical transformation, rather than optimize a Z,E-FOH production strain. 
Fortunately, we were able to take advantage of a wealth of existing research in terpene 
production in E. coli [vide infra], allowing us to quickly design a set of production 
strains.  
Previous work in optimizing the MEP pathway in E. coli has identified 1-deoxy-
D-xylulose-5-phosphate (DXP) synthase (dxs) and DXP reductoisomerase (dxr) gene 
expression as key bottlenecks in terpene production37,. In one study using E. coli 
engineered to produce the downstream terpene isoprene, overexpression of both enzymes 
increased the downstream production by 50%. Interestingly, the overexpression of the 
codon-optimized homologous B. subtillis dxr and dxs enzymes improved the yield a 
further 3.3-fold over the native enzymes, possibly due to the overall higher flux through 
the MEP pathway in B. subtillis38. High expression of 2-C-methyl-D-erythritol 4-
phosphate cytidylyltransferase  (ispD), 2-C-methyl-D-erythritol 2,4-cyclodiphosphate 
synthase  (ispF), and isopentnyl diphosphate isomerase (idi) were also found to enhance 
overall terpenoid production in E. coli39-41. To increase the availability of these precursors 
for terpene synthesis, we overexpressed codon-optimized versions of B. subtillis dxs, dxr, 
idi, ispD, and ispE genes from a plasmid. To produce the desired Z,E-FOH in E. coli, we 
transformed a separate plasmid into the host strain containing one of four  E. coli-codon 
optimized cis-farnesyl pyrophosphate synthase (Z,E-FPPS) enzymes from four acid fast 
bacteria (Mycoplasma. tuberculosis, pFPP242; Thermobifida. fusca, pFPP343; 
Cornybacterium efficiens, pFPP444; Cornybacterium glutamicum, pFPP544) expressed 
from an IPTG-inducible promoter [Figure 2-2].  
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Figure 2-2: Detailed schematic of the E. coli Z,E-FOH production strains. The orange 
plasmid contained components of the B. subtillis MEP pathway. Orange arrows in the pathway 
(top) and in the plasmid (bottom) represent overexpressed enzymes. The green arrows represent 
the heterologous Z,E-FPPS.  
	  
2.2 Results 
2.2.1 Flask production 
The E.coli production strains were constructed by our collaborators at Acidophil LLC. 
They performed several initial tests to optimize the Z,E-FOH production protocol, 
determining that the Z,E-FOH yields were improved by inducing the Z,E-FPPS 
expression at 30°C, and by using a higher (0.2mM) IPTG concentration. Both of these 
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that FPPS2, strain expressing the M. tuberculosis Z,E-FPPS produced the highest yields 
of Z,E-FOH [data not shown.] 
	  
Figure 2-3: Initial characterization of the E. coli production strains. (A) Comparing FOH 
production yields of cultures in which the FPPS was induced at an OD600 of 0.4 (blue) with 
cultures induced at an OD600 of 1.5 (red). The “E. coli” strain at the far left inducibly 
overexpressed the native E,E-FPPS, ispA. (B) Growth curves of base E. coli strain BL21 (yellow) 
growth with FPPS2 (M. tuberculosis) strain growth at 30°C and 37°C, and with and without a 20% 
decane overlay.  
We first tested whether induction of the Z,E-FPPS in the exponential growth 
phase or in early stationary phase produced more Z,E-FOH. Induction at OD600=1.5 
showed superior yields to induction at OD600=0.4 in all the FOH producing strains. A 
comparison of the strains also showed FPPS2’s superior Z,E-FOH production, which 
Acidophil had already observed. All production fermentations from this point forward 
were done exclusively with FPPS2. GC-MS chromatograms and spectra for strains 
FPPS2, FPPS3, FPPS4, and FPPS5, as well as the concentration calibration curve may be 
found in Appendix 1.  
Next, we confirmed that growth at 30°C and a 20% decane overlay did not inhibit 
the growth of the E. coli. Decane and dodecane overlays have been used to great effect in 
the bioreactor production of the advanced terpenoid amorpha-4,11-diene by removing the 
hydrophobic farnesol from the media as it is secreted45. As expected, neither the 
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addition of certain hydrophobic oils and detergents such as soy oil and isopropyl 
myristrae has also been shown to improve terpene yields in a similar mechanism46. 
Initially, we planned to grow the cells with the cheaper and less toxic isopropyl myristate 
in the media. Unfortunately, the isopropyl myristate is difficult to separate from the Z,E-
FOH in the extracts. The presence of the isopropyl myristate prevented the use of a GC-
MS to quantify Z,E-FOH production, as it created a large peak that completely obscured 
any possible Z,E-FOH peak in the chromatograph, as well as being  very difficult to 
remove from the machine injector. Instead, we proceeded with decane overlays in the 
flasks. 
2.2.2 Bioreactor Production 
Any semi-synthetic strategy hinges on 
biosynthesizing quantities of the 
intermediate molecule sufficient for 
subsequent chemical derivitization. 
Unfortunately, while the FPPS2 strain 
reached significant yields, that production 
rate was only attained at small volumes, 
meaning that production of an adequate 
amount of product would require prohibitive numbers of flasks and shaker area. We 
estimated that approximately 50mg of Z,E-FOH would be required to perform three or 
four key transformations. All the fermentations in [Fig 2-3] were done in 50mL LB 
media in baffled 125 mL flasks. Initially, we attempted to scale up flask size to 200mL 






Figure 2-4: Bioreactor Schematic. 
	   51	  
more than negated the 4X increase in volume [Fig 2-6A]. Instead, we constructed a 
simple 6L bioreactor and transferred our production to it to reach our 50mg production 
goal.   
 Briefly, this bioreactor consisted of a reaction vessel holding 2.5-5L of media, an 
L-shaped sparger through which air was introduced into the media, a separate port for air 
outflow connected to a moisture trap, and a water bath which maintained the media at 
29°C [Fig 2-4]. Both the air inflow and outflow were rendered sterile by 0.2µm filters. A 
list of parts for the bioreactor may be found in Appendix 1. To speed production, three 
bioreactors were constructed and were housed in large water baths at three setup sites in 





















Figure 2-5: Final E. coli prenyl alcohol production. A comparison of Z,E-FOH and E,E-FOH 
yields (mg/L)of  from engineered E. coli strains containing one of four bacterial Z,E-FPPases. 
Bars	  	  represent an average of four trials with standard error shown.	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The primary advantage of the bioreactor was the exponentially increased volumes 
of culture grown in each trial. As seen in [Fig 2-5], increasing the volume of the 
production culture once again had a negative impact on yield rates (a reduction of 
approximately 60%), but the 500X greater volume resulted in a greater net product, and 
ultimately successfully produced 50mg of Z,E-FOH over multiple runs.  
	  
Figure 2-6: Scale-up optimizations. (A) Large LB flask cultures. Standard deviation 125mL-2.4 
avg 6 runs; 2L 24h-0.04; 2L 48h-0.005 mg/L avg 2 runs. (B) Production on LB/glycerol/48h at 
each of the three bioreactor setups. Standard deviation W-0.23; Y-0.30; Z-0.15. Average of 3-5 
runs. (C) Comparing LB media with LB media plus 1% glycerol pulses at 12 and 24 hours post-
induction. Standard deviation LB-0.12, LB/2G-0.22 mg/L; avg 4 runs. (D) Comparing LB media 
and TB media with no glycerol pulses, when volume is replenished at 24h post-induction. 
Standard deviation LB-0.38; TB-1.2 mg/L; avg 2 runs.  
  
Consistently, when culture volumes were increased, yields per mL of culture decreased. 
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surface area. In professional fermenters, increased aeration is possible through mixing 
mechanisms. However, this hypothesis could not be tested in this system due to our 
inability to measure the dissolved oxygen content.  
Our bioreactor protocols were largely adapted from those used to ferment a 
different terpenoid, amorpha-4,11-diene, in the Keasling lab45. Attempts informed were 
made to improve production in the bioreactor, including experimenting with periodic 
pulses of glycerol, and different complex growth media [Fig 2-6C, D]. We were not able 
to measure a several key parameters such as pH, dissolved oxygen content due to the 
basic setup, and the reactor itself was prone to varying amounts of media loss through 
evaporation. The bioreactor setup site used also exerted a strong influence on production 
yields [Fig 2-6B].  As a result, production during the optimization process was highly 
inconsistent, although general trends could be observed and were used to develop the 
protocol used for the measurements in [Fig 2-5].  
2.3 Discussion 
In this chapter we demonstrate the strategy of “jigsaw” semi-biosynthesis through the 
production of a series of Ambrox and novel analogs from biosynthetic Z,E-Farnesol. In 
contrast to previous demonstrations of semi-biosynthesis that relied on the production of 
intermediates in the natural pathways, we intentionally explored methods to access broad 
categories of natural product scaffolds via biosynthetically derived, unrelated but 
structurally-relevant precursor molecules not present in the natural pathway. 
In this study, we successfully biosynthesized 50mg of Z,E-FOH in an academic, 
unspecialized laboratory. In addition to developing affordable benchtop methods of 
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valuable natural product production, we also investigated the capabilities of two Z,E-
FPPS enzymes from  C. efficiens and C. glutamicum which have not been previously 
used for biosynthesis. While the M. tuberculosis Z,E-FPPS was the most productive in E. 
coli, the small amount of Z,E-FOH produced by the C. glutamicum Z,E-FPPS suggests 
that it has potential for further metabolic engineering purposes. The production of 
unnatural isomers of natural products can also clarify questions about downstream 
enzymatic transformations. As with many secondary metabolites, E,E-FPP is a substrate 
for several downstream processes in E. coli15. We hypothesized that Z,E-farnesyl 
pyrophosphate (Z,E-FPP) would not be diverted into downstream biosynthetic processes 
due to the altered geometry about the double bond. We observed no such downstream 
products in our extracts, and during the course of our investigations, an independent 
report confirmed these predictions36. 
A key factor in the choice of a biosynthetically derived intermediate for the 
“jigsaw” strategy it that this intermediate carries sufficient functionality and complexity 
for facile conversion to complex natural and unnatural products, while not containing 
overly restrictive architecture to limit its utility to a single natural product. For example, 
the stereospecificity conferred by the Z,E-FPPS of the biosynthesized Z,E-FOH led to 
pure Z,E-homoFOH in the flask. By contrast, when members of our lab developed a 
method to derive Z,E-homoFOH from commercial E,E-FOH, the method yielded a 
mixture of stereoisomers in which the E,E-homoFOH was favored 2:1 over the Z,E-
homoFOH, and required additional purification. 
Z,E-FOH also retains its chemical flexibility; as an acyclic molecule, it lends 
itself to reactions that are difficult or impossible with a more restricted precursor. In 
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contrast, sclareol, the longstanding Ambrox starting material, already contains the 
labdane core, restricting the majority of chemical derivitizations to the tetrahydrofuran 
ring, and leaving the remainder of the molecule’s core unexplored1,31. 
After the successful biosynthetic production of Z,E-FOH, other members of our 
lab were able to chemically transform it into a number of Ambrox analogs via halonium-
induced polyene cyclization47, including 3-Bromo-9-epi-Ambrox and 3-Iodo-9-epi-
Ambrox.  These molecules represent a novel subclass of ambergris odorants in that they 
break the tri-axial rule48 yet retain a strong fragrance. This may indicate that factors other 
than the three axial methyl groups are responsible for conferring the characteristic 
ambergris scent. These analogs are also poised for further chemical modifications due to 
the introduction of a halogen handle during cyclization.  
 This combined “jigsaw” approach thus has successfully produced a set of 
complex natural product analogs derived from an unnatural precursor molecule. The 
careful choice of the biosynthetic precursor facilitated feasible biosynthetic production 
and took advantage of the stereospecificity of biocatalysts while leaving enough 
flexibility to easily perform a range of chemical transformations, rapidly converting a 
single precursor into a family of intriguing analogs. This strategy is not specific to 
terpenes; many classes of molecules could be similarly created. We have explicitly 
highlighted this structure-based approach to assembling a semi-synthetic production route 
as an important conception of semi-synthetic production.  
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2.4 Experimental Methods 
Culture media 
LB media was made from Miller powdered mix (broth:10285, plates:10283), TB media 
was made from BD-Difco powdered mix (243820). 99 % glycerol (G5516), D-(+)-
glucose (G7021), ampicillin sodium salt (A0166) and spectinomycin dihydrochloride 
pentahydrate (S40014) were purchased from Sigma-Aldrich. 
Strain construction 
E. coli BL21 (DE3) cells were chemically transformed with plasmid pA8 (constituitively 
overexpressing a subset of the B. subtillis MEP pathway) and with one of four plasmids 
carrying various Z,E farnesol pyrophosphate synthases (Z,E-FPPases) under an IPTG-
inducible promoter. The four Z,E-FPPases were derived from various species of bacteria 
and codon-optimized for expression in E. coli: M. tuberculosis/RV1086 (pFPP2), T. 
fusca/Tfu0456 (pFPP3), C. efficiens/CE1055 (pFPP4) and C. glutamicum/uppS1 
(pFPP5). E. coli transformants were selected on LB plates containing 50 mg/L 
spectinomycin (for pA8) and 100 mg/L ampicillin (for pFPPs).  
Plasmid construction 
Four Z,E-FPPases previously identified in four species of bacteria[2] (M. 
tuberculosis:RV1086, T. fusca:Tfu0456, C. efficiens:CE1055, and C. glutamicum:uppS1) 
were codon-optimized for expression in E. coli and synthesized commercially by DNA 
2.0 Inc. Each of the four Z,E-FPPases was amplified by PCR (see Table S3) to add NcoI 
and XhoI restriction sites on the 5’ and 3’ ends respectively. The resulting amplicons and 
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pTrc2B vector were digested with NcoI and XhoI, and the construct inserted via InFusion 
cloning (Clontech), to create the four IPTG-inducible Z,E-FPPase expression plasmids 
pFPP2, pFPP3, pFPP4 and pFPP5. The cloning mix was transformed into 
electrocompetent E. coli TG1 cells and selected on LB/ampicillin agar plates. This 
cloning was performed by our collaborator Acidophil LLC. 
Plasmid pA8 containing the B. subtilis MEP pathway was also constructed by Acidophil. 
It consists of a pCL1920 backbone[3] with a replication origin from pSC1010 and 
carrying a spectinomycin resistance cassette. It contains the B. subtilis MEP genes dxs, 
dxr, ispD, ispF, ispG, ispH and idi, which were codon-optimized for E. coli expression. 
The genes were cloned under the IPTG-inducible pLac promoter. B. subtilis genes were 
chosen due to the higher flux through the MEP pathway in B. subtilis compared to E. 
coli[4]. 
Small scale production trials 
E. coli farnesol production was performed in sterilized, baffled, 125 mL Erlenmeyer 
flasks (Corning 4444-125) with culture caps (KimKap 73665-25) in an incubator shaker 
(New Brunswick, Innova 43R). On Day 1, a single colony was inoculated into a 14 mL 
Falcon culture tube containing 3 mL LB with 100 mg/L ampicillin and 50 mg/L 
spectinomycin. The culture was shaken at 37 °C and 230 rpm for 15 hours. On Day 2, 0.5 
mL of the saturated overnight culture was added to 50 mL of LB with 1% glycerol, 100 
mg/L ampicillin and 50 mg/L spectinomycin. The flasks were grown at 30°C and 230 
rpm until they reached an optical density (OD600) of approximately 1.5 (4-6 hrs) as 
determined by a 1:10 dilution of the culture in LB media. OD600 measurements were 
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carried out in a SpectraMaxPlus 384 spectrophotometer using 1.5 mL cuvettes (VWR, 
97000-586). At this point, IPTG was added (0.2 mM) to induce expression of the MEP 
pathway components and Z,E-FPPase. An overlay of 4.5 mL of decane (95 %, Sigma 
30570) was added at the time of induction. The culture was harvested on Day 3 after 24 
hours post-induction.  
Bioreactor production 
Benchtop bioreactor scale E. coli production was performed in a Bellco 6 L Low Profile 
Vertical Sidearm Bioreactor vessel. Filtered air was supplied via a sidearm sparger, and 
vented via two exit ports equipped with moisture traps (see Fig.S6). The 6 L vessel was 
placed in a water bath to maintain the temperature at 29.5 °C. Mixing of the broth was 
achieved by the sparged air. There was no control of dissolved oxygen, pH, nutrient 
availability or culture volume. Bench scale production was attempted only with the 
FPP2/A8 E. coli strain. 
On Day 1, a single colony was inoculated into a 14 mL Falcon culture tube containing 3 
mL LB with 100 mg/L ampicillin and 50 mg/L spectinomycin, and grown at 37 °C and 
230 rpm for 8 hours. The 3 mL culture was then used to inoculate 25 mL of the same 
media and incubated for 15 hours at 37 °C and 230 rpm. On Day 2, the 25 mL overnight 
culture was added to 2.5 L of TB broth and 1 % glycerol (autoclaved at 250 °F for 45 
minutes on Day 1) in a 6 L vessel, along with 400 µl of Sigma Antifoam-400, 100 mg/L 
ampicillin and 50 mg/L spectinomycin. The culture was grown until it reached an OD600 
of approximately 0.3 (4-6 hours), at which time 0.2 mM IPTG was added to induce 
expression of the Z,E-FPPase RV1086 and MEP pathway components. 375 mL of decane 
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was added to the 6 L vessel at the time of induction to form an overlay. Pulses of glycerol 
(25 mL, 1 % of final vol) were added at 8 and 16 hours post-inoculation. At 24 hours 
post-inoculation, 1 L of TB media containing the aforementioned concentrations of IPTG 
and antibiotics was added to replace media lost via evaporation from the 6 L vessel. A 
further 250 mL of decane was also added at this time to replenish the overlay. 6 L vessels 
were collected and extracted at 48 hours post-induction. 
Prenyl alcohol extraction 
Small scale flask fermentations were transferred into a 50 mL falcon tube. The inside of 
the flask was rinsed with 5 mL of ethyl acetate (99.5 %, Sigma 437549), and combined 
with the fermented broth. 1 mL of brine was added to aid separation. The tube was 
vortexed vigorously for 4x30 seconds. The tube was then centrifuged at 3200 rpm for 10 
minutes and the top organic layer was filtered and transferred to a glass GC-MS vial for 
analysis. 
Bench scale fermentations were transferred into a 2 L separation funnel in batches of 1 L. 
500 mL of ethyl acetate and 20 mL of brine were added to each batch in the funnel, and 
the contents shaken vigorously. Separation was allowed to occur and the aqueous layer 
was removed and re-extracted once more as above. The organic layer was transferred into 
centrifuge tubes and spun at 4000 rpm for 10 minutes to break the emulsion. The top 
organic layer was recovered, combined with organic layers from other batches and 
rotavapped to remove the ethyl acetate. The concentrated product was dissolved in 
hexane for analysis (99 %, Sigma 32293). 
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Analysis of prenyl alcohols 
Z,E-FOH, E,E-FOH, nerolidol, GGOH and squalene were analyzed using a 
ThermoFinnigan PolarisQ GC-MS (Agilent J&W column, #CP8907, VF-1 ms 15 m X 
0.25 mm x 0.25 µm). GC-MS runs were carried out with the following method: MS: ion 
source 225 ºC, EI/NICI, mass range 50-600. GC: helium gas, 1.2 ml/min, inlet 
temperature 225 ºC, initial column temperature 50 ºC, hold 2.5 minutes, raise at 17 
ºC/min to 285 ºC, hold 3.5 minutes. 
For quantitative analysis of E. coli fermentations, cis-nerolidol (96 %, Sigma 72180) was 
used as an internal standard. A standard concentration curve was created by graphing the 
ratio of the TIC area of the E,E-farnesol (96 %, Sigma 277541) peak to the TIC area of 
the 25 mg/L cis-nerolidol peak for a range of E,E-farnesol concentrations (Fig.S7). To 
determine the concentration of Z,E-FOH in the biosynthesis extracts, each sample was 
dosed to achieve a final concentration of 25 mg/L cis-nerolidol. The equation of the 
linear regression of the standard curve was used to calculate the concentration of Z,E-
FOH[6]. All production values were back calculated and reported as mg/L of culture 
media. Specifically, the total amount of extracted Z,E-FOH was calculated by 
multiplying the determined concentration by the volume of the extract. This was then 
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2.5 Strains, Plasmids and Oligos Used in this Study 
Table 2-1. Strains used in this study 
Strain Genotype Source/Reference 
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
New England 
Biolabs 
FPPS1 BL21 [pA8, pFPPS1] This study 
FPPS2 BL21 [pA8, pFPPS2] This study 
FPPS3 BL21 [pA8, pFPPS3] This study 
FPPS4 BL21 [pA8, pFPPS4] This study 
FPPS5 BL21 [pA8, pFPPS5] This study 
 
Table 2-2. Plasmids used in this study 
Plasmid Details Source/Reference 
pA8 pSC101-pLac-(dxs, dxr, ispD, ispF, idi, ispH) Alper[37]; this study 
pFPPS1 pBR322-pTrc-E.coli E,E-FPPS This study 
pFPPS2 pBR322-pTrc-E.coli codon-optimized Z,E-
FPPS from M. tuberculosis 
Schulbach [42]; this 
study 
pFPPS3 pBR322-pTrc-E.coli codon-optimized Z,E-
FPPS from T. fusca 
Ambo [43]; this 
study 
pFPPS4 pBR322-pTrc-E.coli codon-optimized Z,E-
FPPS from C. efficiens 
Ambo [44]; this 
study 
pFPPS5 pBR322-pTrc-E.coli codon-optimized Z,E-
FPPS from C. glutamicum 
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3.1.0 Chapter Outlook 
The twenty-first century brought with it new and increased demands for novel biofuels, 
pharmaceuticals, and environmentally friendly industrial practices1. As techniques in 
DNA synthesis, genome sequencing and high-throughput screening continue to improve, 
the horizon of exciting bioproduction possibilities expands every year2. Despite a few 
landmark achievements, however, “white” production technologies have largely not yet 
delivered on their promises.  
A key bottleneck contributing to this discrepancy is the difficulty in constructing 
optimized multi-gene biosynthetic pathways in model organisms. Current techniques of 
DNA assembly were developed for single-gene manipulation, and are ill suited for these 
modern multi-gene pathway constructions3. Furthermore, developing successful 
bioproduction organisms requires the optimization, not simply the construction, of these 
heterologous pathways4. The complexity of even simple metabolisms ensures that the 
purely rational optimization of a pathway is often difficult or impossible, particularly 
when incorporating genes from poorly understood organisms5. The use of complex 
libraries to circumvent these gaps in our knowledge makes the construction of highly 
diverse libraries in vivo a key aspect of many modern applications6-8. Even relatively 
small libraries of metabolic pathways have been shown to have an enormous impact on 
biosynthetic yields9 . Advances in high-throughput screening further expand their utility 
to non-selective applications10. Efficient techniques to create large libraries of extended 
biosynthetic pathways are critical to the success of future applications11.  
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3.1 Introduction 
3.1.1 Multi-gene pathway assembly in vitro 
The complex cloning requirements of pathway optimization and combinatorial 
biosynthesis have far outstripped the capacities of traditional methods of in vitro 
assembly. Many new methods of in vitro DNA assembly have arisen to fill this gap.  
New in vitro tools can create libraries of staggering size12, but constructs generated in 
such a manner must ultimately be assembled and moved into a host cell. Several 
techniques are based on DNA homology. Perhaps the most prominent is the Gibson 
Assembly method13. In a Gibson Assembly reaction, an equimolar mixture of DNA 
fragments with homologous termini are mixed with three enzymes: a T5 exonuclease 
degrades the 5’ ends, exposing the complementary 3’ ends of each fragment, which then 
anneal. The high-fidelity Phusion DNA polymerase fills in any gaps, and Taq ligase seals 
the breaks. As all three enzymes are able to work at 50°C, this process does not require 
thermal cycling, which can damage extremely long pieces of DNA. This method has 
proven effective with fragments of sizes ranging from a few dozen base pairs to hundreds 
of kilobases, and can join multiple fragments at a time without a scar.  
Many natural biosynthetic pathways such as polyketide synthases (PKSs) or non-
ribosomal peptide synthetases (NRPSs) contain highly repetitive sequences, which can 
preclude the use of homology-based assembly methods. While this is not a factor in 
traditional restriction digestion and ligation reactions, assembling large DNA fragments 
in such a manner requires many tedious cloning steps, finding multiple restriction 
endonucleases without additional digestion sites within large fragments becomes 
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increasingly challenging, and the addition of digestion sites generally leaves a scar 
between assembled fragments. The Golden Gate assembly method14 is able to circumvent 
these difficulties in a homology-independent manner by the incorporation of Type IIS 
restriction sites outside of the DNA fragments. Type IIS restriction endonucleases cleave 
at a defined distance outside of their recognition sites. As the endonucleases do not define 
the overhangs and the recognition sites are cleaved off of the fragment prior to ligation, 
the assembly can be scarless. Since the overhangs are asymmetric, multiple fragments 
can be digested by a single enzyme, and assembled in a single step, without the 
possibility of the fragments assembling in the wrong order.  
These methods are robust and can be highly efficient. However, these methods 
have all been developed for plasmid assembly, which requires additional methods for 
integration into the genome. The stability of integrated pathways is particularly desirable 
for industrial applications15. Furthermore, as the number of fragments to be assembled 
rises, the efficiencies of the above techniques drop severely, hampering simultaneous 
diversification of multiple steps in the pathway of interest. Tedious preparations of the 
constructs in E. coli and subsequent host transformations are still required. Landmark 
achievements such as the assembly of a complete bacterial genome from chemically 
synthesized DNA fragments16 have suggested the potential power of in vitro methods, but 
the fundamental challenge of moving these constructs into the cell remains unaddressed.  
3.1.2 Multi-gene pathway assembly in vivo 
The direct assembly of DNA pathways inside the cell has been the subject of much 
interest. CRISPR techniques facilitate alterations to any site in the genome, including 
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incorporation of new genes, and have been employed to alter a small number of sites 
simultaneously17.18. Other homologous recombination based techniques such as gap-
repair cloning19 or delitto perfetto20 have been used for many years, with increasing 
refinement. However, these techniques were developed for the manipulation of a single 
gene or handful of genes. While they have been used to create small libraries, their 
efficiency is greatly reduced with attempts to extrapolate these techniques for large 
libraries of pathways.  
For example, Shao and colleagues developed DNA Assembler, which has 
thoroughly optimized multi-fragment gap repair to construct large biosynthetic pathways 
in a plasmid in one step21. A version of the Assembler can also target the pathway to delta 
sites in the yeast chromosome by URA3 selection. The ura3 gene is placed between two 
repeats to facilitate looping out of the marker, thereby allowing it to be recycled.  While 
the Assembler process is valuable, it has several significant limitations regarding the 
creation of libraries of long pathways. First, while the stability of integration is desirable 
for industrial purposes, integrating to delta sites raises the possibility of varying copy 
numbers, which could easily obscure differences between constructs, as well as 
prohibiting further integration later on. Second, construction of long pathways requires 
large homology regions (~400bp for a 29.1kb pathway) on each fragment to maintain 
efficiency. This works well for reconstituting natural gene clusters22, and does not 
prohibit PCR-based mutation techniques, but the addition of such long homology regions 
is burdensome for applications such as combinatorial biosynthesis or homolog shuffling.  
Finally, as with in vitro techniques, the efficiency of multi-fragment assembly 
significantly restricts the potential library size; single transformations yielded only tens or 
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low hundreds of recombinants. In a notable application of this technique, Kim et al were 
able to create their 1x10^4 plasmid library only through pooling multiple transformation 
steps prior to selection23. 
Another exciting way to make build multiple changes quickly and easily in vivo is 
Multiplex Automated Genome Engineering (MAGE)24. MAGE was used to improve 
biosynthesis of aromatic amino acid derivatives in E. coli by creating a combinatorial 
promoter library for twelve different operons in a matter of days. Transformations at all 
locations were carried out simultaneously, and cells with multiple integrations were 
enriched by co-selection with an unrelated marker. While the scale and speed with which 
this was carried out is undeniably impressive, it should be noted that this technique 
requires an expensive piece of equipment, and the indirect selection resulted in many 
incomplete strains being mixed in with the completely transformed strain library.   
The future challenges of bioproduction require a method that combines the efficiency of 
in vitro techniques with the simple workflow of in vivo methods. To maximize the impact 
of such a method, it must be affordable and accessible so that a broad range of research 
groups can take advantage of the power of combinatorial libraries.  
3.1.3 Reiterative Recombination 
Reiterative Recombination [Fig 3-1] is a method of in vivo DNA assembly 
introduced by our lab as a solution to the challenges of low efficiency and limited 
selection markers in multi-gene pathway assembly in Saccharomyces cerevisiae7. 
Previous work in targeted gene disruption had demonstrated that introducing double-
stranded breaks (DSBs) at the site of recombination greatly increases efficiency of 
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homologous recombination25. “ReRec” builds upon this technique by incorporating into 
its design two orthogonal homing endonucleases and their large (~18bp) recognition and 
cleavage sites. Two selective markers are alternated to conserve marker use even in long 
	  
Figure 3-1: General Scheme of Reiterative Recombination The ReRec system introduces an 
acceptor locus at a specific site in the HO gene locus of chromosome IV, which expresses a 
selective marker (HIS3, green) from a pPYK promoter (white), and encodes a cleavage site for 
the homing endonuclease I-SceI (purple triangle). The DNA fragment of interest (orange) to be 
integrated in the first “round” of ReRec is cloned by gap repair in vivo into a donor vector, which 
contains 1) homology to the HO locus (yellow) and to the acceptor site (gray); 2) the cleavage site 
of a second endonuclease, (HO, green triangle); 3) a second selective marker (LEU2, purple) 
without a promoter; 4) an expressed URA3 marker to select for successful plasmid 
transformation; and 5) the I-SceI endonuclease under the control of a galactose-inducible 
promoter (purple.) Upon galactose induction, the endonuclease is expressed from the donor 
vector and introduces a double-stranded break in the acceptor locus, thus greatly increasing the 
efficiency of recombination. Recombination between the donor vector and the acceptor locus 
introduces the gene of interest and exchanges the first marker for the second. As only the 
integrated selection marker is expressed, recombinants can be easily selected. The donor vector 
can then be cured from the transformants by plating on FOA media. The second DNA fragment of 
interest (dark orange) is cloned into the second round donor vector that inducibly expresses the 
HO endonuclease (green) and the SceI cleavage site (purple triangle). The second DNA fragment 
of interest is integrated directly adjacent to the first fragment via homologous recombination. The 
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assemblies. Each DNA fragment of interest is first cloned into a donor vector, and then 
integrated by homologous recombination into the acceptor site in the yeast genome as 
part of a larger cassette [Fig 3-1]. Cassettes are flanked by short (~20-30bp) regions of 
homology to the acceptor site immediately downstream of the promoter and to either the 
chromosomal locus or to the proceeding fragment. The vector contains one of the homing 
endonucleases under an inducible promoter, and the genome contains the corresponding 
cleavage site. The DNA fragment of interest is integrated together with a new selective 
marker, and the cleavage site for a second endonuclease. As only the selective marker on 
the chromosome is expressed, it is easy to identify recombinants. The resulting 
recombinants are also prepared for a second integration, employing the second homing 
endonuclease and selecting recombinants based on the re-exchange of the second 
selective marker for the original. Thus, by recycling the site-specific endonucleases and 
the two selection markers, the natural efficiencies of homologous recombination in yeast 
are greatly augmented by the introduced DSB, while extensive selection is not required.  
Reiterative Recombination was a major improvement for the insertion of multi-
gene pathways in yeast due to its efficiency, stability, and conservation of selective 
markers. ReRec can easily create large libraries of combinations by transforming multiple 
variants of the inserted DNA into the donor vector at each gap repair step, and collecting 
multiple colonies of integrants for the next round’s transformation culture. Even modest 
libraries of 10^2 targeted variants inserted at each round for five rounds creates a final 
library of 10^10 combinations, which is well beyond the transformation limits of yeast26. 
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3.2 Design of Reiterative Segregation 
We have now expanded our ReRec technology to facilitate rapid construction and 
crossing of combinatorial libraries of biosynthetic pathways. We have brought the 
stability and efficiency of ReRec together with the natural meiotic randomization created 
by the yeast sexual reproduction cycle for a new system that we have termed “Reiterative 
Segregation” or “ReSeg.”  
 Chromosome segregation is a longstanding tool in yeast genetics. Yeast 
mating and subsequent tetrad analysis has been used for decades to construct novel 
strains, combine multiple mutations or genes, and to determine complementation groups. 
Perhaps the most extensive expansion of traditional strain construction via sexual 
assortment is the “Green Monster” system of combining multiple knockouts into a single 
strain27. Suzuki and coworkers created sixteen strains, each with a separate GFP-marked 
deletion of a member of the ATP-binding cassette transporter family. These strains were 
constructed in parallel, and then mated and sporulated to combine the deletions. 
Combination strains were selected by flow cytometry assisted cell sorting (FACS) on the 
basis of GFP intensity.  In this manner, Suzuki et al rapidly constructed the final 
complete deletion strain, as well as a number of interesting deletion combinations. 
Incorporating diversity through mating has also been famously demonstrated in advanced 
yeast two-hybrid systems28 in which a single haploid cDNA library of “prey” proteins in 
one strain is mated with a strain expressing a specific “bait” protein in order to identify a 
successful bait-prey interaction29. This allows a single bait to be tested against many 
thousands of potential interacting partners, without necessitating arduous individual 
constructions and matings. However, to our knowledge sexual assortment has not been 
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used in a lab setting to create true combinatorial libraries, despite the fact that the 
creation of diversity is the principal function of meiosis in nature. We exploited the 
randomization created by chromosome segregation to further diversify existing libraries 
in our novel system.  
	  
Figure 3-2: The Use of Mating to Create Combinatorial Libraries. Each member of an 
individual haploid library strain is mated with each member of a second haploid library strain to 
create a second, larger library of combinations.  
The concept of Reiterative Segregation is straightforward: multiple strains of 
different mating types containing acceptor sites in different chromosomes are created, 
and used as parent strains for the parallel construction of haploid library strains. These 
strains are then combined through mating to exponentially increase the library of 
combinations [Fig 3-2].  After sporulation, the selected spores could then be further 
diversified through mating with other library strains to reiteratively, exponentially 
increase the number of combinations.   
As discussed above, Reiterative Recombination is able to create libraries of 
metabolic pathways through the integration of variants at each construction step. While 
X
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ReRec is an easy way to generate diversity in a single strain, a number of features make 
Reiterative Segregation better suited to library building in multiple pathways, or in long 
pathways. While each ReRec integration step only takes approximately one week, a 
library of seven or eight genes still represents a significant time investment in 
construction. As the number of combinations grows, it becomes more technically tedious 
to transform sufficient cells at each step to ensure complete coverage of the library. Many 
bioproduction applications require multiple functions in a single organism, and the ability 
to construct and/or partially optimize separate pathway-specific libraries individually 
before attempting to combine them could facilitate the identification of ideal 
combinations. ReSeg’s multiple ReRec strains would allow users to build and diversify 
multiple pathways, or to split and speed construction of a lengthy pathway [Fig 3-3]30.  	  
	  
Figure 3-3: General Design of Reiterative Segregation: Beginning from the top right of the 
figure, two haploid libraries are mated to produce a greater diploid library. This pool of diploids is 
then sporulated to create a haploid library of greater complexity, which can then be mated again 
with a third haploid library to iteratively increase the diversity of the resulting strain. This cycle 
may be continued to incorporate all desired haploid libraries.  
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As a proof of concept, we created and tested a second ReRec strain of the 
opposite mating type, in which the acceptor locus was integrated into the TYR1 locus of 
chromosome II. The lycopene biosynthetic pathway was divided between the two strains 
and was successfully reconstituted by the ReSeg system. 
3.3 Results 
3.3.1 Construction of the Reiterative Segregation System 
Reiterative Segregation requires at least two strains of opposite mating type equipped 
with the ReRec modifications [Fig 3-4A]. The ReRec parental strain (LW2591) was 
constructed in the background of BY473331. LW2591 was used as the MAT-A parent  
	  
Figure 3-4: ReSeg Mating. (A) Haploid strains (top) are able to reproduce mitotically. When 
haploid strains of opposite mating type encounter each other, mitotic growth stops, and the cells 
project towards each other and then fuse, forming a diploid cell. The diploid can reproduce 
mitotically, but under starvation conditions undergoes meiosis to form four haploid spores. (B) 
The Reiterative Recombination integration process into the acceptor sites of the MAT-A parent (i) 
and the MAT-α parent (ii).  
strain of ReSeg, while the MAT-alpha parent strain was constructed in the same BY4733 
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background strain BY4733 has relatively low rates of mating and sporulation. 
BY4733had been chosen to ease strain construction and pathway assembly: its complete 
deletions of the leu2 and ura3 loci, and hisdelta200 are essential to prevent inappropriate 
recombination during ReRec’s gap repair step. Indeed, the ReSeg system was initially 
constructed in the FY250/FY25132 background, which has an improved mating 
phenotype, but its auxotrophy is derived from transposon insertions or point mutations, 
rather than complete deletions. While the construction was ultimately successful, 
extensive sequencing of the strain’s genome was required at every step. After many 
inappropriate side recombinations were observed in each transformation and integration 
steps, the system was moved back to BY4733. For more advanced ReSeg applications we 
plan to construct the strains in an appropriate deletion strain that is better suited to the 
mating and sporulation steps. 
 Construction of the alpha-type ReSeg strain consisted of two steps: first, a 
version of the acceptor site initially expressing Leu2 was amplified by PCR from 
pLW2654. Sixty base pairs of flanking homology to the TYR1 locus was added by PCR, 
and the acceptor site was integrated into the TYR1 locus of a BY4733 MAT-A strain. 
Secondly, the pop-in/pop-out plasmid33 pLW2586 was used to exchange the MAT-A 
locus for a MAT-alpha locus incorporating the inc3-534 mutation to create CP90. The HO 
endonuclease naturally cleaves in the MAT loci35 to stimulate mating-type switching in 
haploid strains The silent inc3-7 mutation changes the second base pair of the Z1 region 
from G/C to A/T, destroying the HO recognition site and preventing unwanted HO 
cleavage and mating-type switching during HO induction on alternate rounds. This does 
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not affect expression of transcription factors from the MAT loci or impact mating 
ability36. The Sce-I endonuclease is encoded in the mitochondria, and has no natural  
	  
Figure 3-5: ReSeg Validation. The lycopene biosynthetic pathway is recapitulated by mating 
and sporulation. The final spore has a phenotype that combines that of its parents (HIS3, LEU2) 
as well as a novel phenotype of its own (orange.) 
cleavage sites in the yeast nuclear genome37. TYR1 was chosen as the site of the acceptor 
locus as heterologous genes integrated at that site were known to express well38, and 
because yeast media is routinely supplied with tyrosine, making TYR1 expression 
redundant. A new initial donor vector pCP66 was constructed by adding a region of 
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even-round donor pLW2592, which contains a His3 coding sequence.  After the first 
round, the even and odd round donors previously constructed for the original ReRec 
system could be used as odd and even round donors, respectively [Fig 3-4B]. 
3.3.2 Validation of the Reiterative Segregation system 
To demonstrate the ability of ReSeg to construct variation in components of one 
metabolic pathway in parallel, we devised a proof of principle using the heterologous 
lycopene pathway [Fig 3-5].   
	  
Figure 3-6: The construction of the lycopene biosynthetic pathway. (A) The heterologous 
lycopene pathway in yeast. (B) The division of the relevant genes and the final auxotrophies of 
the two ReSeg strains. 
Lycopene can be produced in yeast by incorporating three carotenoid genes crtE, 
crtB and crtI [Fig 3-6A]39. We integrated the yeast-codon-optimized versions of Erwinia 
herbicola crtE, crtB and crtI, as well as an additional copy of S. cerevisiae fad1, a FAD 
synthetase40. As crtI is a FAD-dependent enzyme, co-expression with fad1 was expected 
to improved lycopene speed and production based on previous work (unpublished data).  
The crtE and crtB genes were previously integrated into the original ReRec strain 
LW2591 to create LW2670, while crtI and fad1 were integrated into the new alpha 
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successfully reconstituted the entire lycopene pathway, and thus exhibited both the 
orange phenotype and the double selection [Fig 3-7].   
	  
Figure 3-7: Successful recapitulation of the lycopene pathway. The MAT-α parent, CP84, the 
MAT-A parent, LW2670, and the mated diploid, CP92, each have a unique phenotype.  
3.3.3 Characterization of the lycopene phenotype 
Unexpectedly,	   the	   diploid	   strain	   CP92	   exhibited	   visibly	   less	   lycopene	   production	  
than	   the	  haploid	   strain	   LW2671,	  which	   contains	   all	   three	   carotenoid	   genes	   in	   the	  
original	   ReRec	   locus	   without	   fad1[Fig3-­‐8A].	   To	   explore	   whether	   this	   was	   due	   to	  
poor	   expression	   of	   crtI	   from	   the	   TYR1	   locus	   or	   to	   ploidy-­‐related	   expression	  
regulation,	  we	  mated	  LW2671	  with	  CP90	  to	  create	  CP103.	  CP103	  expressed	  visibly	  
less	  lycopene	  then	  either	  LW2671	  or	  CP92,	  indicating	  that	  the	  ploidy	  state	  of	  the	  cell	  
was	  the	  major	  factor[Fig3-­‐8A].	  	  	  
There	  were	  a	  number	  of	  possible	  explanations	  for	  this	  result:	   first,	   that	  this	  
ploidy-­‐dependent	   effect	   is	   specific	   to	   terpenoid	   production,	   as	   changes	   in	   the	  
production	  of	  sesquiterpenes	  between	  diploids	  and	  the	  two	  mating	  types	  have	  been	  
reported	   due	   to	   the	   haploid	   MAT-­‐a	   selective	   expression	   of	   mating	   pheremone	   a-­‐
factor,	  which	  contains	  a	  farnesyl	  group	  derived	  from	  FPP41-­‐43.	  Secondly,	  changes	  in	  
membrane	   sterol	   content	  have	  also	  been	   reported	  between	  diploids	  and	  haploids,	  
and	   could	   be	   drawing	   the	   metabolic	   flux	   away	   from	   the	   competing	   heterologous	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genes	   in	   the	   HO	   locus	   is	   negatively	   impacted	   by	   the	   natural	   suppression	   of	   HO	  
expression	   in	   diploid	   cells45,46.	   To	   clarify	   this	   result,	   we	   next	   sporulated	   CP92	   to	  
CP102	   (MAT-­‐a)	   and	   CP109	   (MAT-­‐α).	   While	   the	   A-­‐type	   spores	   were	   much	   more	  
orange	  on	  the	  plate,	  this	  was	  not	  reflected	  in	  liquid	  culture	  measurements.	  	  
Another	   intriguing	   result	   is	   the	   distinct	   and	   highly	   reproducible	  











































Figure 3-8: Lycopene production in 96-well plates: The production of lycopene is markedly 
higher on HL- media versus complete media in certain strains. However, the haploid strains do no 
produce as much lycopene in liquid media as on solid media, where the A-type strain is markedly 
redder than the diploid or alpha-type.  
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is	   linked	   to	   the	   terpenoid	   pathway	   through	   the	   metabolic	   intermediate	   PRPP,	  
previous	   work	   in	   E.	   coli	   showed	   an	   opposite	   correlation,	   linking	   histidine	  
production	   with	   lower	   lycopene	   yields47.	   However,	   in	   diploids	   it	   showed	   the	  
opposite	   effect,	   perhaps	   due	   to	   increased	   overall	   metabolic	   flux.histidine	  
biosynthetic	  	  
	  
3.3.4 Construction of libraries via Reiterative Segregation 
To compare the scale of the ReSeg system to the original ReRec system, we 
simulated integrating libraries of variants by creating versions of LW2670 and CP84 in 
which nonsense mutations had been introduced into the crtB and crtI alleles, to create 
LW194 and CP101 respectively. We then created pools of strains in which the cells 
expressing the functional allele were diluted into different ratios of cells expressing 
nonsense allele, to represent a desired variant in a library of nonfunctional variants. 
	  
Figure 3-9: Library phenotypes. (A) Different diploids formed when mating the two lycopene 
libraries. All the diploids have the HIS3/LEU2 phenotype, but only those rare colonies that had 
functional versions of both crtB and crtI exhibited the orange phenotype. (B) An orange colony 
(marked by a red arrow) on a library plate.  
The strain pools were then mated with each other and the resulting colonies 
screened for the orange phenotype. Cells expressing nonsense mutations in either or both 
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were recovered in the expected ratios, demonstrating the successful combination of the 
two “libraries” [Table 3-1].  
	  
Table 3-1: Lycopene biosynthesis pathway library mating.  
3.4 Discussion 
Reiterative Segregation is a valuable extension of the existing Reiterative Recombination 
system, and expands its application in the context of metabolic pathway engineering.  
Chromosome segregation has been used to create strains for decades. While new 
techniques have extended its assembly powers to the fullest, chromosome segregation has 
never before been used to create libraries. Reiterative Segregation embraces meiosis’ 
fundamental purpose of maintaining genetic diversity48, and uses that intrinsic capability 
to rapidly assemble combinatorial libraries from smaller libraries in haploid strains.  
We view ReSeg as one of a set of complementary tools in the synthetic biology 
toolbox. The variation comprising the libraries is enhanced by other components of the 
Strain Dilution Ratios









10 : 1 0 : 1 10^1 2052 220 10.72%
100 : 1 0 : 1 10^2 1920 39 2.03%
0 : 1 10 : 1 10^1 437 42 9.61%
100 : 1 100 : 1 10^4 17913 1 0.01%
10 : 1 10 : 1 10^2 597 6 1.01%
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toolbox—different homologs or functional equivalents of key enzymes identified by 
genomics, synthetic promoters to tune expression levels, or mutated enzymes created by 
directed evolution. The in vivo process removes cumbersome plasmid purification steps 
that are often detrimental to large DNA fragments, but its separate assembly and 
integration steps also permit early in vitro assembly or mutation steps, such as error-
prone PCR to create random mutations in a subfragment to be integrated, or Gibson 
Assembly cloning of a fragment with highly repetitive internal sequences. The stability of 
the incorporated DNA makes it ideal for further strain improvement through evolutionary 
engineering, and the recycling of markers leaves ample selections for mass integration or 
plasmid transformation after assembly. Naturally, it also allows quick comparisons 
between the diploid and both haploid backgrounds without additional construction. The 
speed of parallel versus sequential construction facilitates the assembly of multiple long 
metabolic pathways, while the mating creates a number of possibilities.  
In addition to the exponential increase in combinations with each round of 
mating, we can envision applications in which one precursor molecule is transformed into 
a number of different complex target molecules.  A strain of one mating type could 
contain a library of enzymes intended to optimize production of the particular metabolic 
precursor, and could be individually mated with a set of different strains each containing 
a library to optimize the same precursor to a different complex target molecule. This 
would optimize production of a set of related target molecules, finding the best method of 
precursor production for each downstream diversification. 
By constructing libraries in parallel and then combining them through mating, 
incredible levels of diversity may be achieved. A single extended pathway can be split up 
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into manageable pieces; multiple useful phenotypes can be rapidly combined in a single 
organism; different precursor libraries can be combined with different downstream 
modification libraries to optimize production of a set of related molecules in parallel. 
Reiterative Segregation provides a stable, robust, and technically simple way to introduce 
the power of combinatorial libraries to the development of novel metabolic pathways.  
3.5 Experimental Methods 
Construction of the Reiterative Segregation Strain CP90: The ReRec parent strain 
LW2591 was used as the MAT-A ReSeg parent, and the MAT-α ReSeg parent CP90 was 
constructed in a similar fashion. A version of the acceptor site in which the first marker is 
LEU2 was amplified from plasmid pLW2654 by oCP35 and oCP36. Approximately 60 
base pairs of homology to the Tyr1 locus were added through PCR with oCP231-6. A 
culture of BY4733 MAT-A was made competent for electroporation according to 
standard methods, and was transformed with >1ug of the acceptor amplicon via 
electroporation as described elsewhere# to create CP68. Successful integrants were 
selected by leucine auxotrophy and confirmed though PCR assays using oCP237 and 
oCP238 as well as sequencing. A pop-in/pop-out vector pLW2586 containing MATX, Y-
α-inc3-7, and Z1 regions and a URA3 selection marker was linearized by digestion with 
NheI according to manufacturer protocols and purified through agarose electrophoresis 
and Qiagen column extraction. The digested integrative vector was concentrated using 
Pellet Paint Co-Precipitant product, and >1ug of vector was transformed into CP68 via 
electroporation as above. Integrants were selected by uracil auxotrophy and confirmed by 
PCR and sequencing. One confirmed “pop-in” colony was grown in liquid culture 
without uracil selection for 3 days, and plated on leucine-/FOA plates. Individual “pop-
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out” colonies were assayed by PCR and sequencing for correct substitution of the Y-α-inc 
region for the original Y-A region. One successful colony was isolated and named CP90, 
and is used as the second ReSeg alpha parent strain.  
Reiterative Recombination Protocol—Round 1 of the α strain 
1)  Amplify DNA fragments of interest in PCR1 and add appropriate homology via in 
PCR2 (see Table3-2). Purify the fragments from gel.   
 
2)  Co-transform the PCR products were co-transformed with the digested ReSeg-α 
donor vector (pCP66) in a 100:1 ratio into the ReSeg-α parent strain CP90. 
Alternatively, in cases of difficult assembly, Gibson assembly may be used to 
verify the correct assembly of the fragments in the donor vector and subsequently 
be transformed into the yeast strain. Transformants are selected on synthetic 
complete media lacking histidine and uracil (see Table 3-3). 
 
3)  After 2-4 days of growth, ~10 transformant colonies are picked from the 
transformation plates and resuspended in 1mL sterile water. Cells are then 
pelleted at 500rpm for 2min, resuspended in 1mL of sterile water again, and then 
divided into two tube is harvested as before, but one pellet is resuspended into 
1mL induction media (SGal/U-: 2% galactose, without uracil to continue selection 
for the donor vector) and the other into induction control media (SC/U’: 2% 
glucose without uracil to continue selection for the donor vector.)  
 
4) 1mL each of induction or control media in 15mL Falcon culture tubes were 
inoculated to an OD600 of 0.1. Induction and control cultures were shaken at 
30°C for 12h.  
 
5)  100µL of the induction culture or the control culture are then inoculated into 
SC/H-liquid media, (2% glucose without histidine to select for successful 
recombinants) shaken at 30°C for 24h, and plated at appropriate dilutions on 
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SC/H-/0.1%FOA plates to cure recombinants of the donor plasmid. Plates are 
grown at 30°C for 2-4 days to develop colonies. 
 
To begin the next round of Reiterative Recombination, a single cured colony (for single 
construction) or an entire scraped plate (for library construction) is inoculated into SC/H- 
media to begin an overnight culture for the next transformation. In subsequent rounds, the 
donor vectors, the primers used to add donor vector homology to the DNA fragments, 
and the type of selective media alternate according to Tables 3-2 and 3-3.  
 
Table 3-2. Cycle-specific DNA preparation for ReSeg-α 
 PCR1 PCR2 Donor Restriction 
Enzymes 
 Add to 5’ end 
of 5’ primer 
Add to 5’ end 
of 3’ primer 
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Figure 3-10: Reiterative Segregation donor vectors.  
Lycopene induction assay49 
The lycopene sensor strains were assayed in 96-well micro titer plates cultured at 30 
°C and 800 RPM. Cells were seeded at an OD600 of 2 in standard complete synthetic 
media (2% dextrose) supplemented with 5% yeast extract peptone dextrose media (YPD). 
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conditions for the yeast device assay (i.e. high cell density and non-selective complex 
media) while enabling more precise spectroscopic determination of lycopene content (i.e. 
higher bulk signal at early time points and low-absorbance media). Under these 
conditions cell number doubled 1.6 times on average over the course of the experiment. 
At the initial time point, assay wells also contained the indicated concentration of 
synthetic peptide or water as a blank control. Optical density measurements at 395nm, 
520nm and 600nm of each well were measured using a Tecan Infinite M200 and relative 
lycopene content was calculated using Eq. v. Lycopene values were normalized by the 
OD600 and scaled to set the lycopene null strain (LW2591) equal to 1 at the initial time 
point. 
To determine the relative lycopene content of a cell suspension we adapted the 
method proposed by Myers et al50 to characterize pigmented cells through optical density 
measurements at multiple wavelengths. This improved method greatly reduces the noise 
due to variations in cell growth phase, cell density and other sample irregularities. This 
enabled the precise evaluation of lycopene content in a high throughput micro titer plate 
format. 
As described by Myers, the optical density of the cell suspension measured at a 
sensitive wavelength (i.e. corresponding to an absorption maxima of the pigment) is 
approximately composed of two additive components: scatter due to cells and absorbance 
due to the pigment. Therefore the pigment content in a cell suspension is proportional to 
the measured optical density corrected for the scattering component as follows: 
i)	  𝑝𝑖𝑔𝑚𝑒𝑛𝑡∝𝐴𝑏𝑠𝑆,	  𝑃=𝑂𝐷𝑆−𝑂𝐷𝑆,	  	  𝑠𝑐𝑎𝑡 
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where AbsS,P is the absorbance due to the pigment at the sensitive wavelength S, ODS is 
the measured optical density at the sensitive wavelength S, and ODS,scat is a calculated 
scattering component at the sensitive wavelength S. Since there was noticeable Raleigh-
like wavelength dependence in the scatter of lycopene null strains we chose the following 
functional form to approximate scatter at a particular wavelength λ: 
ii)	  𝑂𝐷𝜆,	  𝑠𝑐𝑎𝑡=𝐵−log101−𝐴𝜆  
where A and B are constants that reflect changes in cell density and other sample 
irregularities. At each time point and for each sample, we can calculate the corresponding 
values of A and B by using the optical density values measured at two robust wavelengths 
(i.e. corresponding to wavelengths where scatter is the only or dominant component). 
Substituting these additional scatter-only optical density measurements into Eq. ii and 
solving for A and B we get: 
iii)	  𝐴=	  𝑅11	  −	  𝑇𝑅1𝑅2	  −	  𝑇,  where 	  𝑇=10𝑂𝐷𝑅1−	  𝑂𝐷𝑅2  
iv)	  𝐵=	  𝑂𝐷𝑅1+log101−	  𝐴𝑅1 
where ODR1 and ODR2 are the measured optical densities at the robust wavelengths R1 
and R2. Therefore, by setting λ = S and substituting Eq.ii into Eq. iii, the relative content 
of lycopene in a cell suspension is given by: 
v)	  𝑝𝑖𝑔𝑚𝑒𝑛𝑡∝𝐴𝑏𝑠𝑆,	  𝑃=𝑂𝐷𝑆+log101−𝐴𝑆−𝐵  
To apply this method to lycopene in yeast, we determined the appropriate 
sensitive and robust wavelengths by obtaining the absorbance spectrum of lycopene 
directly in yeast cells. The spectrum was determined by subtracting the optical density 
spectrum of a lycopene null strain from that of a constitutive lycopene producing strain. 
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This spectrum showed the characteristic profile of lycopene absorbance and had two 
major absorbance maxima at 485nm and 520nm. Based on this spectrum, 520nm was 
chosen as the sensitive wavelength (S = 520) since it is furthest away from other natural 
chromophores in yeast that absorb below 500nm (e.g. flavins). 395nm and 600nm were 
chosen as two robust wavelengths (R1 = 600 and R2 = 395) with low absorbance from 
lycopene and other natural chromophores. 
Three additional considerations were crucial to yield reproducible lycopene 
measurements in a micro titer plate format. First, all three optical density measurements 
(at 395nm, 520nm and 600nm) were taken at the same time for each well to reduce errors 
due to the settling of cells during the measurement of a whole micro titer plate. Second, 
assay wells were blanked using a reference well on the same micro titer plate containing 
identical media conditions as the assay wells but with out cells. This was particularly 
important when colored media was used. Finally, high cell densities (OD600 ≥ 2) were 
used to yield larger bulk lycopene signals even with the short path length of micro titer 
plates (~3mm). Since these high optical density values were outside the linear range of 
the photo detector, all optical density values were first corrected using the following 
formula to give true optical density values: 
vi)	  𝑂𝐷𝑡𝑟𝑢𝑒=𝑘∙𝑂𝐷𝑚𝑒𝑎𝑠𝑂𝐷𝑠𝑎𝑡	  −	  𝑂𝐷𝑚𝑒𝑎𝑠 
where ODmeas is the measured optical density, ODsat is the saturation value of the photo 
detector and k is the true optical density at which the detector reaches half saturation of 
the measured optical density. Appropriate values for ODsat and k were determined by 
plotting direct optical density measurements of a range of cultures of several strains, 
against the true optical densities determined by dilution to the linear range. Optical 
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densities were taken at 395nm, 520nm and 600nm. All points were fit once with Eq. vi 
using Prism (GraphPad) to give ODsat = 3.57 and k = 3.16. These values were used to 
correct all optical density measurements. 
 
Simulated libraries: Haploid strains were inoculated into 3mL of appropriate selective 
media (H-or L-) in 15mL culture tubes and shaken at 30°C overnight. The following 
morning, the OD600 of each strain was measured, and the equivalent of 1mL of culture at 
OD600=1 were removed to a separate tube. The tubes were spun down 30s at 14,000rpm 
in a minifuge, and the supernatant aspirated. Each pellet was resuspended in 1mL sterile 
water. Serial dilutions of the strain containing the wild-type lycopene gene into the strain 
containing the lycopene gene with a nonsense mutation were then performed to obtain 
1mL mixes of the correct wild-type:stop ratios. The mixtures were spun down as above, 
and the supernatant aspirated. The pellet corresponding to each MAT-α strain and the 
pellet corresponding to each MAT-A strain were resuspended together in 1mL sterile 
water. This mixture was then plated onto YPD plates, which were left upside-down at 
30°C for 8 hours. The plates were then scraped into 1-2mLs of sterile water, spun down 
as before, and resuspended in 5mL of media selective for the diploids (HL-) in 15mL 
culture tubes. The tubes were shaken at 250rpm and 30°C for 24 hours to eliminate the 
unmated haploids.  The cultures were then spun down as before and resuspended in 1mL 
sterile water to ensure consistent volumes. These cultures were then plated on selective 
(HL-) media in dilutions appropriate to obtain single colonies. The plates were then 
grown at 30°C for 3 days and evaluated for lycopene production.  
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3.6 Strains, Plasmids and Oligos Used in this Study 
Table 3-4. Strains used in this study 
Strain Genotype Source/Reference 
BY4733 MAT-A his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 
ATCC200895 
LW194 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 HO::HIS3 ReRec acceptor 
[pTEF-crtE-tADH, pPGK-crtB-E14*-tACT] 
Wingler [7] 
LW2589 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 
Wingler [7] 
LW2591 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 HO::HIS3 ReRec acceptor 
Wingler [7] 
LW2670 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 HO::HIS3 ReRec acceptor 
[pTEF-crtE-tADH, pPGK-crtB-tACT] 
Wingler [7] 
LW2671 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 




CP84 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::LEU2 ReRec acceptor [pGPD-
crtI-tCYC, pPGK-fad1-tACT] 
This study 
CP90 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::LEU2 ReRec acceptor  
This study 
CP92 LW2670/CP84 This study 
CP101 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::leu2 ReRec acceptor [pGPD-
crtI-G8*-tCYC, pPGK-fad1-tACT]  
TYR1::LEU2 ReRec acceptor [pGPD-crtI-G8*-
tCYC, pPGK-fad1-tACT] 
This study 
CP102 MAT-A his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::LEU2 ReRec acceptor [pGPD-
crtI-G8*-tCYC, pPGK-fad1-tACT] HO::HIS3 
ReRec acceptor [pTEF-crtE-tADH, pPGK-crtB-
tACT]  
This study 
CP103 LW2671/CP90 This study 
CP109 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::LEU2 ReRec acceptor [pGPD-
crtI-G8*-tCYC, pPGK-fad1-tACT] HO::HIS3 
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Table 3-5. Plasmids used in this study 
Plasmid Details Source/Reference 
pLW2586 Digest with NheI to form integration plasmid 
exchanging MAT-α-inc for MAT-A via pop-
in/pop-out technology. URA3, 2µ.  
 
Wingler [7] 
pLW2592 LEU2/HO donor vector. Ura3, CEN Wingler [7] 
pLW2593 HIS3/Sce-I donor vector. Ura3, CEN Wingler [7] 
pLW2594 MAT-A Round 1(HO homology) LEU2/HO 
donor vector. Ura3, CEN 
Wingler [7] 
pLW2654 Plasmid to integrate pPYK-GFP-LEU2 into HO 
gene locus. 2µ 
Wingler [7] 
pCP66 MAT-α Round 1 (Tyr1 homology) His3/Sce-I 




Table 3-6. Oligos used in this study 












oCP232 CAA ATC ATA TGA TCA TAT GGA TCA ATA CCA AGT TGA AAC 
CAC GAA TCA ACA ATC GCC AAC 
oCP233 TTAATTCTGTTATGGCATGTTTGAAAAGTAAGCAAGTTTATTTGA
CATATGAAGAGCATG 
oCP234 ACC CAG GAA TAT TCT GAA TAA TGG CGT CGA ACA AAT CAT 
ATG ATC ATA TGG ATC AAT ACC 
oCP235 AATCACAGATCACAGTACCCAGAATCTTTTGAGTTCGTTAATTCT
GTTATGGCATGTTTG 
oCP236 AGC CAG GTT TTA AAA AAA GAT ATT CGG ACA CAC CCA GGA 
ATA TTC TGA ATA ATG GCG TCG 
oCP237 CGTCGCAACGTATGGACCATCTTCTAAGGTTGGAACAATTGTTGG
G 
oCP238 CAT CTC GTT GCC AAT GAG ATT AGC CTC TGG AAG CAT TGG C 
oCP373 CGA AGG CTT TGC ATG CTG CAG GAT AAA CAT GGT ATA AGA 
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GGA TAA GAT TGA GC 
oCP374 CGG TAC CCG GGG ATC CTC TAG AGT CGA GTG TCA CAG CTT 
GTG TAT CAG CG 
oCP375 CTTGCTTGAGAAGGTTTTGGGACGCTCGA AGG CTT TGC ATG 
CTG C 
oCP376 TTA TAC TGT TGC GGA AAG CTG AAA GAA TTC GAG CTCGG 
TAC CCG GGG ATC CTC TAG 
oCP383 GCATGACAAGATTACCGCTGATACACAAGCAGTTTATCATTATCA
ATACTCGCCATTTC 
oCP384 CTG TTG CGG AAA GCT GAA ACA AAT TAA AGC CTT CGA GCG 
TC 









oCP442 TTG TTT TAT ATT TGT TGT AAA AAG TAG ATA ATT ACT TCC 
oCP475 GCA GGT TTT GGT GGT TGA GCT TTG G 
oCP477 GCA GAA GCT ACA ACT CCA GGA ATA CC 
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4.0 Chapter Outlook 
In this chapter, we expand on the ReSeg system’s capabilities, and work on 
relevant applications for ReSeg. 
Once the basic design of ReSeg had been validated by the recapitulation of the 
lycopene pathway, we were interested in whether we could develop features that would 
streamline the system further. One feature that we experimented with was adding 
additional selections to improve the efficiency of the mating step, and ensuring that 
mating could take place with every construction of ReSeg strains. We incorporated the 
expression of virally-expressed yeast killer toxin proteins1 to use as a unique selection. 
The killer phenotype was successfully developed, but further work will be required to use 
it for diploid selection.  
We also wanted to challenge our system and demonstrate ReSeg’s expanded 
potential for large libraries.  The lycopene phenotype was easy to identify, but it required 
extensive screening to evaluate, which limited the size of the testable library to 104, since 
every variant must be examined individually.  A selection is required for larger libraries, 
and growth selection, in which only the desired variants survive, is straightforward to 
evaluate. We decided to incorporate metabolic pathways that would allow ReSeg strains 
to grow on the alternative sugars xylose, arabinose, and maltose. A mix of these and other 
sugars are present in most biofuel feedstocks2, making the combination of these 
phenotypes relevant to industrial applications, as well as easy to develop. In this process, 
we demonstrated growth on xylose and maltose, as well as learned more about the kinds 
of pathways with which ReSeg is best used.  
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4.1 Introduction 
4.1.1 Incorporating yeast killer toxins into the design of ReSeg 
Efficient mating of the two ReSeg strains requires the ability to select for diploids. 
Depending on the number of integration rounds in each strain, this selection is provided 
by the different auxotrophic markers in each strain: when one ReSeg strain is expressing 
the HIS3 marker and the other is expressing the LEU2 marker, diploids may be found by 
selecting on media without histidine or leucine. However, in cases where one strain has 
had an even number of integration rounds and the other strain has had an odd number of 
integration rounds, the two strains will both be expressing the same selective marker, and 
an extraneous integration will be required to be able to mate the strains effectively.  
 We wanted to alter the strains in such a way that they would always mate, 
regardless of the auxotrophic markers in the acceptor sites. This alteration would ideally 
not use up a common selection marker that could be useful in other aspects of strain 
construction, would not require expensive or difficult techniques to maintain, and would 
not interfere with biosynthesis yields by placing significant stress on the host cell 
metabolism. Additional markers would also facilitate the identification of the desired 
spores. We decided to employ yeast toxins of viral origin to create this selection.  
 In 1963, certain strains of yeast were found to express a “killer” phenotype under 
certain circumstances3. These yeasts secreted toxins that induced programmed cell death 
in sensitive yeasts, while the protoxin or preprotoxin forms provided self-immunity to the 
specific toxin. Killer yeast toxins in a number of yeasts4,5 are encoded by double-stranded 
RNA (dsRNA) viruses. In S. cerevisiae, these viruses are of the family Totiviridae in the 
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mycovirus class6. Four major killer viruses have been discovered in S. cerevisiae 
specifically: ScV-M17, ScV-M28, ScV-M289, and ScV-Mlus10. Each of these viruses 
contains a single ORF, which encodes the preprotoxin (pptox). Expression of each pptox 
is sufficient to confer both the killer phenotype and the self-immunity to the host cell11.  
Although the pptoxs have no DNA or amino acid sequence homology to each 
other, and they have similar structures and processing: the pptox is translated in the 
cytoplasm, and consists of an N-terminal signal sequence followed by a moderately 
hydrophobic alpha subunit, a linking gamma sequence, and finally a hydrophilic beta 
subunit12.13.  After translation, the N-terminal signal sequence mediates translocation into 
the endoplasmic reticulum via the Sec61 pore complex. In the ER, the pptox is processed 
in a manner very similar to insulin14. Part of the N-terminal signal sequence is cleaved 
off, and the gamma-sequence in N-glycosylated, and a disulfide bridge is formed between 
the alpha and beta subunits. In the late Golgi, the endogenous Kex2 protein cleaves the 
remains of the N-terminal signal sequence and the gamma-sequence, creating the mature 
alpha/beta heterodimeric killer K toxin, which is then secreted. Cells expressing one type 
of pptox remain sensitive to the other three toxins. Fascinatingly, the mechanisms by 
which these functions are carried out are unique to each pptox.  
 The K1 and K2 toxins are ionophoric toxins that behave similarly to zygocin15. 
Both K116 and K217 bind to the cell wall beta-glucan receptor before transfer to the 
plasma membrane in a sensitive cell. Although its primary target has not been 
conclusively identified, K1 toxin is known to bind to Kre1 receptor18 on the plasma 
membrane. K2 toxin is also thought to bind to Kre119. The result of both K1 and K2 is the 
disruption of the plasma membrane integrity leading to cell death20,21,22. K1 is believed to 
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inhibit Na+/K+ pumping, while K2 is believed to integrate into the plasma membrane 
and form cation-leaking pores directly23.  
In a contrasting mechanism, the K28 toxin contains an HDELR epitope on its C-
terminal. In the late Golgi, the terminal arginine is cleaved off by the host 
carboxypeptidase Kex1, revealing the HDEL ER retention signal24. The K28 toxin then 
interacts with the HDEL receptor (possibly Erd2) of the targeted cell. The K28 toxin is 
then take up via receptor-mediated endocytosis25, and is transported back to the target’s 
ER in a manner similar to other toxins such as ricin and cholera toxin26. K28 once more 
makes use of the Sec61 pore to travel to the cytoplasm, where the beta subunit is 
ubiquinated and degraded by the proteasome, thus freeing the small (10.5 kDa) alpha 
subunit to diffuse into the nucleus. Inside the nucleus, K28 kills the cell by interfering 
with proteins required for DNA synthesis and cell cycle regulation27.  The Klus toxin 
killing function is not yet known11. 
Expression of each pptoxs not only confers the “killer” phenotype to a host cell, it 
also provides self-immunity from its own killing activity. The mechanisms for this 
immunity are as varied as the killing mechanisms. In cells infected with ScV-M1 or ScV-
M2, a portion of the K1 and K2 toxins retain their N-terminal signal sequence, and thus 
remain attached to the plasma membrane. These membrane-bound toxins compete with 
the mature toxins for binding to the cell-surface receptor, preventing toxic 
interactions28,29.  In ScV-M28 killer cells, after the K28 alpha/beta heterodimer has 
reentered the cytoplasm of the killer cell, it is bound by the freshly translated pptox. This 
complex cannot enter the ER, and ubiquitination of the beta subunits of both the 
heterodimer and the pptox direct the entire complex to the proteasome29.  
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 While these killer toxins are expressed from dsRNA viruses in nature, cDNA 
sequences of the pptoxs have been used to express the toxins from plasmids, successfully 
conferring both the killer phenotype and the immunity7,8,30. Even a “triple killer” strains 
has been made, which expresses K1, K2, K28 toxins from cDNA31. At high 
concentrations of killer toxins, sensitive cells die via necrotic or cytotoxic cell death32, 
while low toxin concentrations trigger programmed cell death pathways33,34. Thus, we 
hypothesized that a single copy of a K1 or K2 toxin cDNA integrated into the genome 
would be sufficient to confer the killer phenotypes to the ReSeg strains. Sensitive strains 
are known to survive exposure to killer strains if the two strains fuse or mate35. 
Therefore, we decided to put a cDNA copy of the K1 toxin into the acceptor site of one 
ReSeg strain, and a cDNA copy of the K2 toxin into the acceptor site of the other in order 
to confer a diploid selection regardless of the expressed auxotrophic markers. 
Unfortunately, the low gene dosage of the toxins proved insufficient to use as a selection. 
However, we discuss the explanations for these unsatisfactory results, and propose 
possible methods to develop toxin selections.  
 
4.1.2 Library Applications to Biofuels 
ReSeg was designed to build medium libraries in parallel, and then combine those 
libraries into one large combinatorial library. The lycopene screen in Chapter III was 
sufficient to examine a library of 104, but is impractical for a larger library. A growth 
selection would permit access to much larger numbers of variants. A simple method of 
selection in vivo is a growth selection36, in which the desired variants of a library have the 
most rapid growth rate, and accordingly dominate the culture.  
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The ever-expanding biofuel industry provided industrially relevant pathways to 
develop. Bioethanol fermentation by yeast has a very narrow energy margin, partly due to 
the fact that much of the feedstock is not consumed37. S. cerevisiae is a robust and 
efficient cell factory for ethanol fermentation38, but it does not naturally consume many 
of the components of common hemicellulose feedstock, including xylose, maltose and 
arabinose39,40.  
 Extensive work has been done to engineer S. cerevisiae to ferment xylose41. 
Generally, this is accomplished by incorporating enzymes from one of the many species 
of bacteria, yeasts, and non-filamentous fungi that are naturally able to ferment xylose to 
ethanol. In bacterial, the first step of xylose metabolism is the isomerization of xylose to 
xylulose by xylose isomerase (XI)42. In most fungi, xylose is converted to xylulose in two 
steps; first to xylitol using xylose reductase (XR) and then to xylulose by xylitol 
dehydrogenase (XDH). The xylulose is then phosphorylated to xylulose-5-phosphate, 
which can then enter the pentose phosphate catabolic pathway [Fig4-1]. S. cerevisiae 
does not encode XI, XR, or XDH, and the native XK is not expressed highly enough to 
permit growth. While xylose isomerase-based yeast strains were later created43, the first 
S. cerevisiae strains to successfully ferment xylose to ethanol incorporated the P. stipitis 
XYL1 (XR) and XYL2 (XDH) genes, as well high expression of either the P. stipitis or 
the native XK44.  
Arabinose is a more recent target for metabolic engineering, but significant gains 
have been made in the last twenty years45. As with xylose metabolism, there are two 
general forms of arabinose metabolism, one found in bacteria and one found in fungi. The 
bacterial pathway is redox-neutral and consists of three enzymes: an arabinose isomerase  
	   108	  
	  
	  
Figure 4-1: The fungal xylose metabolic pathway as incorporated into S. cerevisiae. The 
xylose is transported using endogenous hexose translocators with affinity for pentose sugars, like 
GAL2.  
(AI) which converts L-arabinose to L-ribulose, a ribulokinase (RK) which converts L-
ribulose to L-ribulose-5-phosphate, and a L-ribulose-5-phosphate epimerase (RE), which 
converst L-ribulose-5-phosphate to D-xylulose-5-phosphate [Fig4-2]. By contrast, the 
fungal pathway is not redox-neutral, and consists of five enzymes. Both heterologous 
pathways have been expressed in S. cerevisiae, but significant arabinose fermentation has 
only been achieved with the bacterial arabinose metabolic pathway.  
Two key factors in the success of initial arabinose fermenting strains46 were the 
high overexpression of B. subtillis AI and E. coli RE from strong promoters on high-copy 
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expression level requirements were also observed in the construction of a fully integrated 
strain in which a single copy of E. coli RK was integrated into the genome, and multiple 
copies of both B. subtillis AI and E. coli RE 	  
	  
Figure 4-2: The bacterial arabinose metabolic pathway as incorporated into S. cerevisiae. 
Arabinose is transported using hexose transporters, as with xylose. In strains expressing the P. 
stipitis xylose reductase, a significant portion of the L-arabinose is converted into L-arabitol, 
instead of proceeding to the pentose phosphate pathway. High expression of AI reduces this side 
product.  
were mass integrated into the rDNA47. This highlighted a possible difficulty in 
successfully expressing the arabinose utilization pathway from a single chromosomal site 
as in ReSeg. However, we reasoned that recent improvements in heterologous expression 
of these genes might be able to compensate for the lower gene dosage. In other studies 
examining many different AI homologs, arabinose utilization was greatly improved in 
strains expressing the B. lichenformis AI homolog. The enzymatic activities of the 
different isomerase homologs could not be measured directly, but growth and protein 
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expression levels were recorded. Suggestively, strains expressing the B. lichenformis 
isomerase reached their maximal specific growth rate far faster than those expressing B. 
subtillis isomerase, despite having a lower protein expression level48.  Codon-optimizing 
the isomerase for S. cerevisiae usage further improved the maximal growth rate from 
0.08h-1 to 0.112h-1.  Given these improvements, we hypothesized that some improved 
growth on arabinose would be observed when the pathway was incorporated into ReSeg. 
Our initial goal was to make a small library of the xylose-utilization pathway in 
one ReSeg strain, and a small library of the arabinose utilization pathway in the other. 
We would then combine them through mating and evaluate which combinations 
produced the most effective co-utilization of the sugars. These two valuable metabolic 
pathways are a logical combination that would be advantageous in a single strain47. 
Combining libraries of arabinose and xylose utilization pathways was particularly 
appealing as a ReSeg demonstration since XR is known to convert L-arabinose to arabitol 
in competition with AI, which has a negative impact on overall growth and ethanol 
production49.  Finding a combination of homologs which minimized side product 
formation would be an elegant use of the ReSeg system.  
Maltose utilization was also explored, to serve as an alternative in the event that 
the activity of AI and RE remained too low when expressed from the acceptor site. 
Maltose is present in many types of biofuel feedstocks40, so it is a relevant phenotype to 
explore. Many strains of S. cerevisiae are MAL+, meaning they naturally consume 
maltose; maltose is a major ingredient in brewery fermentations. Most laboratory strains 
however are mal—50. The genes required to utilize maltose are encoded by the MAL loci, 
five highly homologous unlinked sites spread throughout the S. cerevisiae genome51. 
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Each locus (named MAL1, MAL2, MAL3, MAL4, or MAL6) contains a maltose 
permease (1), a maltase (2), and a transcription factor (3)52 that activates the other two 
proteins when glucose is absent and maltose is present53. The genes are named according 
to their locus and function; for example, the permease from the MAL6 locus is named 
MAL61.  
	  
Figure 4-3: The MAL6 locus organization and expression. Mal63 is inhibited by the presence 
of glucose and activated in the presence of maltose. A small amount of maltose enters the cell 
using other transporters, and activates Mal63, which then binds to the Mal61/63 UAS region to 
upregulate transcription of both the maltose transporter Mal61 and the maltase Mal62. Maltose 
transcription factors from any MAL locus can activate transcription in the other loci.  
Any one of the five loci is sufficient to confer the MAL+ phenotype. In the ReSeg 
background BY4733 (derived from S288C), MAL13 and MAL33 are nonfunctional, and 
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Plasmid expression of S. cerevisiae MAL63 complements the MAL13 and MAL33 
mutations and successfully confer the MAL+ phenotype53[Fig 4-3]. We considered 
variants of MAL63 to create a small maltose utilization library to combine with the 
xylose utilization library, and be evaluated via growth selection.  
 Unfortunately, early testing with the arabinose utilization pathway proved to be 
incompatible with the ReSeg system. While the xylose and maltose utilization pathways 
performed well, difficulties in obtaining and constructing the libraries prevented the 
alternative sugar application from being completed. We discuss the remaining 
construction and potential impact. 
4.2 Results 
4.2.1 Initial testing of the killer phenotype 
Prior to constructing cDNA toxin strains, virally infected strains were employed to 
develop the assay conditions. Diploid strains infected with ScV-M1(SK-S14a) and ScV-
M2 (M471) were a kind gift from Professor Anne-Marie Sdicu’s laboratory at McGill 
University. SK-S14a is a diploid obtained from crossing “superkiller” strain T158c54 with 
a sensitive strain S14a55. Most superkiller strains have mutations that permit higher 
numbers of the dsRNA virus, or facilitate viral translation and processing56; SK-S14a’s 
superkiller phenotype derives from the expression of a K1 toxin with two point mutations 
that is more stable at 30°C than the common K1 toxin. M471 is a diploid isolate from the 
wild57. Initial studies were performed on the S6 supersensitive strain58 before moving to 
the ReSeg parent strains.  
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 Killer assays are generally done in either agar wells or in halo assays. We spotted 
cells onto lawns to observe the halos. K1 toxin is active in a narrow pH range (~4.1-4.8), 
and temperature range (~18°C--25°C) unless it contains the superkiller mutations. K2 
toxin is optimally functional at a lower pH, (~4.0) and is more active at higher 
temperatures, up to 30°C. Sodium concentration can also affect activity. When the killer 
strains are plated in incorrect media, the strains grow normally, but the characteristic halo 
is not formed. After several trials, SK-S14a and M471 were both able to produce halos on 
rich media buffered to 4.5 by succinate and NaOH incubated at room temperature [Fig 4-
4A]. This media was used for all further halo assays. Strong halos were observed for both 
SK-S14a and M471 on S6 lawns, while smaller halos were observed on lawns of 
LW2591, indicating that the ReSeg strain was sensitive, but less sensitive than S6. M471 
were able to grow and produced a smaller halo on lawns of SK-S14a, and SK-S14a 
behaved similarly on lawns of M471, demonstrating the cross-killing ability of the two 
types of toxins.   
4.2.2 Characterization of strains expressing K1 toxin from cDNA 
A 2µ high-copy plasmid containing the K1 cDNA toxin under the control of the strong 
pPGK promoter, pDTMa,59 was a kind gift from Professor Schmitt at the University of 
Saarland.  The K1 coding sequence was amplified and integrated into the low-copy CEN 
ReSeg-A round 1 donor vector pLW2594 to make pCP85. Both pDTMa and pCP85 were 
transformed into ReSeg-A parent strain 2591, and the K1 toxin set was integrated into the 
HO acceptor site. This created three strains with different gene dosages of the K1 toxin: 
CP110 (a single K1 integrated into the genome), CP96 (K1 on a low-copy plasmid), and 
CP111 (K1 on a high-copy plasmid).  
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Figure 4-4: Killer yeast toxin halo assays. (A) Testing halo conditions. Viral K1 and K2 strains 
are able to kill a sensitive strain and each other as evinced by the visible halos, demonstrating the 
independent killer and immunity of the two toxins. (B) Testing K1 strains. (i) SK-S14a viral strain; 
(ii) CP111 (2µ) (iii) CP96 (CEN) (iv) CP110 (integrated 1x). The integrated copy of the K1 cDNA 
does exert a toxic phenotype, as seen on the S6 lawn. However, this halo is invisible on the 
ReSeg parent lawn, showing that the killer phenotype conferred by a single copy of the K1 cDNA 
is insufficient to produce a significant selection.  
To evaluate whether the chromosomal copy was sufficient to confer the killer 
phenotype, equal numbers of cells of the above strains, as well as SK-S14a were spotted 

















i ii iii iv i ii iii iv
	   115	  
phenotype. While the killer phenotype of the chromosomally integrated K1 toxin was 
discernable on the S6 lawn, it was effectively nonexistent on the 2591 lawn. We 
concluded that integrating a single copy of the K1 toxin was insufficient to act as a 
selection in our current ReSeg strains.  
4.2.3 Growth selections on alternative sugars 
Xylose 
We constructed the initial xylose utilization pathway using the P. stipitis XR, XDH and 
the S. cerevisiae XK, as has been previously demonstrated49. Prior to integration via 
ReRec, we cloned the three genes into high-copy plasmids and integrated the three 
plasmids into the ReSeg parent strain 2591 to quickly evaluate the xylose growth 
phenotype in our background. This xylose plasmid strain, CP75, and LW2591 were 
grown in 96 well plates in synthetic complete media containing glucose (SC) or xylose 
(SX) as the sole carbon source [Fig 4-5]. CP75 showed a strong advantage on the SX 
media compared to LW2591, and the high-level expression of all three xylose utilization 
genes did not appear to place an undue metabolic burden in SC media. 
	   We then began to construct the integrated xylose utilization pathway library. We 
chose to vary only the XR enzyme, as it is the enzyme involved in the undesired cross-
reaction with arabinose. Previous studies60 using libraries of xylose enzyme homologs 
showed significant improvement in xylose fermentation derived from a small pool of  
combinations. The XR of Aspergillus flavus was heavily represented in the pool of 
improved xylose fermentation strains, so we planned that the miniature library would 
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consist of the well characterized P. stipitis XR to serve as a positive control, the P. stipitis 
XR with an early nonsense mutation to serve as a negative control, and the A. flavus XR.  
	  
Figure 4-5: Growth phenotype of a plasmid-based xylose utilization S. cerevisiae strain. 
The expression of the xylose metabolic pathway enzymes from a plasmid confer a clear growth 
advantage to CP75 versus the parent strain LW2591 on maltose. The growth of CP75 on glucose 
matches that of the parent 2591, indicating that the high expression of XR, XDH and XK is only a 
minor metabolic burden. All standard deviations were <0.06, and are invisible on this graph.  
Unfortunately, the gene synthesis of the codon-optimized A. flavus XR proved to 
be very time consuming, and contained secondary structures near the termini that have 
prevented strain completion thus far. An additional complication is the significant growth 
of the ReSeg strain containing only XDH and XK, which has prevented functional 
assembly selections, and could potentially complicate library selections by slowing the 
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Our arabinose utilization pathway was assembled using the E. coli RK and RE 
enzymes46, and a codon-optimized version of the B. lichenformis AI48. As with the xylose 
pathway, all three enzymes were first tested on high-copy plasmids. This is a particularly 
valuable test for the arabinose pathway, given the concern over its functional expression 
levels from the chromosome. AI and RE were both under the control of strong, 
constitutive promoters, while RK was placed under the control of a weak constitutive 
promoter in accordance with previous work47,48. These plasmids were transformed into 
LW2591 to create CP77. The growth of LW2591 and CP77 on synthetic complete media 
using only glucose (SC) or arabinose (SA) as the carbon source was compared [Fig 4-6].  
	  
Figure 4-6: Growth phenotypes of a plasmid-based arabinose utilization strain of S. 
cerevisiae.  The expression of the arabinose-utilization enzymes did not confer growth on 
arabinose to CP77. Expression of these enzymes also appears to have a very negative effect on 
the growth rates even in glucose.  
Unfortunately, rather than showing a growth advantage on SA, CP77 grew more 
slowly than the parent strain. One additional variation, in which the RK was placed under 
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Based on these results, as well as the existing literature, it was concluded that the 
bacterial arabinose utilization pathway was not a good candidate for integration and 
variation by ReSeg.  
Maltose 
After the decision to abandon the arabinose utilization pathway was made, we turned to 
maltose, another alternative sugar relevant to biofuel fermentation. A functional copy of 
the MAL63 transcription factor was amplified from a MAL6+ strain RF23161, kindly 
provided by Professor Finley at the University of Wisconsin. MAL63 was placed under 
the strong promoter pGPD, cloned into the ReSeg-α round 1 donor strain pCP66, and 
subsequently integrated into the TYR1 acceptor site to form CP108. CP108 and the 
ReSeg-α parent strain CP90 were both grown on synthetic complete glucose (SC) or 
maltose (SM) media. MAL63 expression successfully restored the MAL+ phenotype, and 
provided a strong selection to incorporate [Fig 4-7]. 
As in the xylose utilization pathway, we planned to construct a miniature library of three 
MAL63 variants. The S. cerevisiae MAL63 was kept as a positive control; a version of 
the cerevisiae MAL63 containing a nonsense mutation to render it nonfunctional would 
serve as a negative control, and a Candida albicans transcription factor affecting sucrose 
utilization and alphaglucosidase activity, previously shown to complement mal63 
mutations, SUC162, would provide an interesting comparison. Unfortunately, SUC1 
contains several regions of very high AT content in the middle of the gene, and many 
extended repeat sequences near the C terminal, meaning that it cannot be synthesized. 
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Amplifying the SUC1 gene from the genome of C. albicans has also proved challenging 
due to poor template DNA.   
	  
	  
Figure 4-7: Growth phenotypes of a constructed MAL+ S. cerevisiae strain. A functional 
copy of MAL63 was integrated into the acceptor site in CP90, and confers excellent growth on 
maltose.  
	   	  
4.3 Discussion 
In this chapter, we attempted to demonstrate the use of Reiterative Segregation in 
complex metabolic pathway applications. First, we examined a technical inefficiency of 
the system (the possibility of both strains expressing the same marker, thus preventing 
efficient mating) and explored a creative potential solution to further streamline the 
ReSeg system. Second, we investigated a number of alternative sugars relevant to the 
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projects have not yet come to fruition, but we believe that they still have potential in our 
lab and in the larger world of metabolic pathway construction.  
The use of yeast killer toxins as selective markers has been demonstrated in other 
systems63: to eliminate contaminating fungi from industrial fermentations64, to select for 
successful induced protoplast fusion35, and has even been explored as a marker for 
successful transformation and to maintain plasmids in the cytoplasm65. Our experiments 
with the toxicity of a single copy of the K1 toxin cDNA on a ReSeg parent strain informs 
us that the phenotype must be significantly enhanced to serve as an effective diploid 
selection. In our opinion however, several factors keep this possibility open.  
First, the K1 toxin expressed was the more common variant, that is particularly 
sensitive to temperatures above 25°C. The K1 toxin expressed by the T158c strain is not 
expressed in higher amounts, but is significantly more stable. This difference alone 
confers T158c’s “superkiller” status.54 Using the T158c mutant variant would likely 
enhance toxicity. Secondly, a stronger promoter such as pGal10 could also strengthen the 
phenotype. Thirdly, only the K1 toxin was examined; it is possible that one of the other 
three toxins might be better suited to the ReSeg strain background and growing 
conditions. Finally, extensive mutation screens have identified a number of mutations 
such as ski5 that enhance the killer phenotype by increasing toxin processing and 
secretion56. Other mutations hypersensitize non-killer cells to K1, K2 and/or K28 
toxins21,55. Depending on the desired application of the ReSeg strain and the pleiotropic 
effects, a small number of mutations to the ReSeg strains could result in effective 
selection without greatly affecting the growth phenotype.  
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ReSeg is designed to create large libraries of multi-gene pathways. While the 
reconstitution of the lycopene biosynthetic pathway in Chapter III demonstrated the rapid 
creation of a combinatorial library, the screening evaluation restricted the library size to 
the number of colonies that could be counted by hand. Large libraries (>106) are can be 
powerful tools in pathway optimization, but they are only as effective as their means of 
evaluation. Using a selection permits access to far greater numbers of variants than what 
is accessible by a screen. By choosing two metabolic pathways that confer distinct 
growth selections, we could demonstrate ReSeg’s advantages in combinations and 
parallel constructions at a much larger scale.  
 The difficulty in successfully reconstituting arabinose metabolism was 
unfortunate, but it clarifies ReSeg’s niche among the many DNA assembly techniques. 
ReSeg creates stable strains potentially incorporating long pathways, but its single 
acceptor site makes it ill-suited for pathways requiring extremely high expression levels. 
It should be noted however, that the recycling of selective markers leaves plenty of 
opportunity to combine a ReSeg construct with other techniques such as mass integration 
or plasmid usage to overcome expression level difficulties.  
In contrast, the maltose utilization pathway is a very good fit for ReSeg. A single 
copy of the maltose regulation transcription factor is sufficient to confer rapid growth on 
maltose. Future work to combine xylose and maltose utilization pathways could 
demonstrate the ease of identifying ideal combinations of different metabolic pathways, 
and provide a valuable template of optimizing multiple heterologous pathways in a single 
organism.  
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4.4 Experimental Methods 
K1 cDNA strain construction 
The K1 cDNA ORF was amplified from pDTMa by oCP356 and oCP357. It was 
integrated into LW2591 to form CP96 and then CP110 by ReRec as described in chapter 
3. CP111 was made by transforming pDTMa into LW2591.  
Halo Assays 
Buffered YPG assay media: 20g glucose, 10g yeast extract, 10g peptone, 10g succinic 
acid, 3g NaOH (Bussey & Meaden 1985 [65] ) was made to both 2% (hard) and 1% (soft) 
agar. 15mL of the hard agar was poured into 100mm plates and allowed to set. The soft 
agar was inoculated to 2x103cells/mL of the lawn strain and 10mL of the mixture was 
poured over the hard agar layer. The layered lawn plates were left at room temperature 
for 6 hours, and then were spotted with the killer strains. The equivalent of 1mL at 
OD600 cells of the assayed strains were collected and resuspended in 1mL of sterile 
water. 5µL of this solution and of 1:10 and 1:100 dilutions of each strain were spotted 
using a multi channel pipette. Plates remained upside-down for the first 24h to minimize 
streaking. Plates were grown at room temperature for 3 days before being photographed.  
Alternative sugar strain construction 
XR was amplified from the gDNA of P. stipitis with homology to pTEF1 and tADH1 by 
PCR using oCP63 and oCP64. XDH was amplified from the gDNA of P. stipitis with 
homology to pPGK and tADH1 by oCP67 and oCP68. XK was amplified from the 
gDNA of BY4733 with homology to pGPD and tCYC by PCR using oCP69 and oCP71. 
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Each was transformed into BY4733-A with digested pRS vector to be assembled by gap 
repair to create the pCP41, pCP54 and pCP55. For integration, the XR set was amplified 
from these high-copy plasmids by oCP328 and oCP329, the XDH by oCP330 and 
oCP331, and the XK by oCP332 and oCP333 and integrated by ReRec as described in 
Chapter 3.  
Codon-optimized B. lichenformis AI was synthesized as two gBlocks by the company 
Integrated DNA Technology. The pieces were joined and acquired homology to pHXT7 
and tADH1 by PCR using oCP72 and oCP73. RK was amplified from E. coli gDNA by 
oCP75 and oCP76. REwas amplified from E. coli gDNA by oCP78 and oCP79. Each 
arabinose plasmid was assembled by gap repair as with the xylose plasmids.  
MAL63 and its endogenous terminator were amplified from the gDNA of RF231 and 
added pGPD and pCP66 homology by PCR using oCP516 and oCP517.  pGPD was 
amplified from BY4733 gDNA and added pCP66 and MAL63 homology by PCR using 
oCP383 and oCP515. They were integrated into CP90 to form CP108 by ReRec, as 
described in Chapter 3.  
Alternative sugar growth assays 
Each strain was inoculated in 3mL selective glucose media shaking at 30°C overnight. In 
the morning, 2 x 1mL of the cells were harvested at 500rpm for 2 min and washed with 
1mL water, spun down as before, and resuspended in synthetic complete glucose or 
alternative sugar media. More of the appropriate media was inoculated to an OD600 of 
0.01, and plated 100 µL/well into a 96 well plate. Each strain/media pair got 12 wells, 
and 6 wells of empty media to be used as blanks. The wells were measured at OD600 by 
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a Tecan igm200, and shaken at 250rpm at 30°C. Each point in the growth curve 
represents the average of all 12 wells corrected for the blanks.  
	  
4.5 Strains, Plasmids and Oligos Used in this Study 
Table 4-1. Strains used in this study 
Strain Genotype Source/Reference 
LW2591 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 HO::HIS3 ReRec acceptor 
Wingler [66] 
CP75 BY4733-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 [pCP41, pCP54, pCP55] 
This study 
CP77 BY4733-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 [pCP40, pCP73, pCP80] 
This study 
CP90 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::LEU2 ReRec acceptor  
This study 
CP96 LW2591 [pCP85] This study 
CP108 MAT-α-inc his3Δ200 leu2Δ0 met15Δ0 trp1Δ63 
ura3Δ0 TYR1::HIS3 ReRec acceptor [pGPD-
Mal63-tMAL63] 
This study 
CP110 MAT-A-inc his3Δ200 leu2Δ0 met15Δ0 
trp1Δ63 ura3Δ0 HO::LEU1 ReRec acceptor 
[pADH1-K1-tADH1] 
This study 
CP111 2591 [pDTMa] This study 
M471 MAT-A/MAT-α   ScV-M2 Sdicu; Naumov [57] 
RF231 EGY49 background, MAT-α MAL+, his3, 
trp1D0::hisG, ura3, 3LexAop-Leu2::leu2, Lys+, 
Gal+  
Finley [61] 
S6 MAT-A Sdicu; Bussey [58] 
SK-S14a MAT-A/MAT-α   ScV-M1 Sdicu; Brizzard [54] 
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Table 4-2. Plasmids used in this study 
Plasmid Details Source/Reference 
pLW2594 MAT-A Round 1(HO homology) Leu2/HO 
donor vector. Ura3, CEN 
Wingler [66] 
pCP40 pRS425-pTEF1-RE(E. coli)-tCYC This study 
pCP41 pRS424-pGPD-XK (S. cerevisiae)-tCYC This study 
pCP54 pRS423-pPGK-XDH(P. stipitis)-tADH This study 
pCP55 pRS425-pTEF-XR(P. stipitis)-tADH This study 
pCP66 MAT-α Round 1 (Tyr1 homology) His3/Sce-I 
donor vector. Ura3, CEN 
This study 
pCP73 pRS423-RK (E. coli)-tADH1 This study 
pCP80 pRS424-pHXT7-AI(B. lichenformis)-tADH1 This study 
pCP85 pLW2594-pADH1-K1-tADH1 This study 
pDTMa pYES-pPGK-K1-tPGK 2µ URA3 Lolle, [59] 
 
Table 4-3. Oligos used in this study 






oCP329 CCG GGC TGC AGG AAT TCG ATA TCA AGC TTA TGA GCG 
ACC TCA TGC TAT ACC TG 
oCP330 ATAAGCTTGATATCGAATTCGCGAATTTCTTATGATTTATGAT
TTTTATTATTAAATAAG 
oCP331 GTG GAT CCC CCG GGC TGC AGA ACA TTT TGA AGC TAT 
AGG GAT GAT AAT GCG ATT AGT CAG 
oCP332 CGAATTCCTGCAGCGCATTATCATCCCTATAGCTTCAAAATG
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TTTCTACTCCTTTTTTAC 
oCP333 CAC CGC GGT GGC GGC CGC TCT AGA ACT AGT GGA TCC 
CCA AAT TAA AGC CTT CGA GCG TCC 
oCP334 CCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCC
TGCAGCGCATTATC 
oCP335 AAA AGC TGG AGC TCC ACC GCG GTG GCG GCC GCT CTA 
GAA CTA GTG GAT CCC CCG GGC TGC 
oCP336 CCG GGC CCC CCC TCG AGG TCG ACG GTA TCG ATA AGC 
TTG ATA TCG AAT TCG CG 
oCP337 AACAAAAAGTTTTTTTAATTTTAATCAAAAAATGTTGCAAAC
CAAGGATTATGAATTCTG 
oCP338 TCA TAA TCC TTG GTT TGC AAC ATT TTT TGA TTA AAA 
TTA AAA AAA CTT TTT GTT TTT GTG 
oCP339 TAC CTG GCG TTT GAG ATC TTC TAA CAT TTT GTA ATT 
AAA ACT TAG ATT AGA TTG CTA TGC 
oCP340 TAG CAA TCT AAT CTA AGT TTT AAT TAC AAA ATG TTA 
GAA GAT CTC AAA CGC CAG 
oCP341 AGG GCG TGA ATG TAA GCG TGA CAT AAC TAA TTT ACT 
GCC CGT AAT ATG CCT TCG 
oCP342 CGC GAA GGC ATA TTA CGG GCA GTA AAT TAG TTA TGT 
CAC GCT TAC ATT CAC G 
oCP343 TCA TAA ATC ATA AGA AAT TCG CTT ATT TTT GCA ATC 
TGT ACA AAG CTT CG 
oCP344 TGTACAGATTGCAAAAATAAGCGAATTTCTTATGATTTATGA
TTTTTATTATTAAATAAG 
oCP345 AGG CTG CCC AGG CCG TTG CGA CTC TAT AAG AGC GAC 
CTC ATG CTA TAC CTG 
oCP346 CTT TCT CAG GTA TAG CAT GAG GTC GCT CTT ATA GAG 
TCG CAA CGG CCT G 
oCP347 CAT TAT CAG ACT AGT GGA TCC CCC GGA TGG CGA TTG 
CAA TTG GCC TC 
oCP348 TCA CTG CCA AAA TCG AGG CCA ATT GCA ATC GCC ATC 
CGG GGG ATC CAC TAG TCT G 
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oCP356 ACTTAATAGAAGGCATTGTATATGAGATAGTTGATTGTATGC
TTGG 
oCP357 GCT CTA GAA CTA GTG GAT CCC CCG GGC CAA CTT CTT 
TTC TTT TTT TTT CTT TTC TCT CTC 
oCP358 AGC ATA CAA TCA ACT ATC TCA TAT ACA ATG CCT TCT 
ATT AAG TTG AAC TCT GG 
oCP383 GCATGACAAGATTACCGCTGATACACAAGC"AGTTTATCATT
ATCAATACTCGCCATTTC 
oCP515 TCG CAA GAC TGT TTC GCA ATA CCC ATT TTG TTT GTT 
TAT GTG TGT TTA TTC G 
oCP516 AAT AAA CAC ACA TAA ACA AAC AAA ATG GGT ATT GCG 
AAA CAG TCT TGC  
oCP517 CTG TTG CGG AAA GCT GAA ACT AGT ACT TAA CAC ATC 
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APPENDIX	  1:	  	  	  	  GAS	  CHROMATOGRAMS	  AND	  MASS	  SPECTRA	  OF	  
BIOSYNTHETICALLY	  PRODUCED	  PRENYL	  ALCOHOLS	  
Figure	  A1-­1.	  GC-­MS	  traces	  of	  E.	  coli	  
FPPS2	  flask	  fermentations	  products	  
in	  decane	  
(A) Gas chromatograms of extract from 
FPP2 (M. tuberculosis Z,E-FPPS) flask 
fermentation in decane (top) and 
synthetic Z,E-FOH standard in decane 
(below). (B) Corresponding mass spectra 
below. Peak (i) denotes the Z,E-FOH 
product of the FPP2 strain. Peak (iii) 
denotes the synthesized Z,E-FOH, and 
peak (ii) denotes a potential degradation 
product of Z,E-FOH. RT of Z,E-FOH is 
~12.12 min. RT of the Z,E-FOH side 
peak is ~12.05 min. These runs were 
performed with a different GC column 
compared to all other traces in this report, 
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Figure	  A1-­2.	  GC-­MS	  traces	  of	  E.	  coli	  
FPPS2	  bioreactor	  fermentations	  in	  
hexane	  
(A) Gas chromatograms of extract from 
FPP2 bench-scale production in hexane (top) 
and the synthetic Z,E-farnesol standard 
(below) in hexane. Corresponding mass 
spectra (B). Peak (i) denotes the added cis-
nerolidol standard. Peak (ii) denotes the 
biosynthesized Z,E-FOH. Peak (iv) denotes 
the synthesized Z,E-FOH, and peak (iii) 
denotes the side peak as in (A). RT of cis-
nerolidol in hexane is ~8.87 min. RT of 
standard Z,E-FOH in hexane is  ~9.98 min. 
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Figure	  A1-­3.	  GC-­MS	  traces	  of	  
E.	  coli	  alternative	  Z,E-­FPPS	  
flask	  fermentations	  
(A) Gas chromatograms of 
extracts from E. coli strains 
containing the other Z,E-FPPases: 
1) FPP5 (C. glutamicum); 2) 
FPP4 (C. efficiens); 3) FPP3 (T. 
fusca); 4) Mix of farnesol isomers 
(Sigma, W247804) in decane; 5) 
Synthesized Z,E-FOH standard in 
decane. Corresponding mass 
spectra (B). Peaks (i), (iv), and 
(vi) denote the added cis-
nerolidol. Peaks (ii) and (vii) 
denote biosynthesized Z,E-FOH. 
Peaks (iii), (v) and (viii) denote 
EE-FOH. RT of cis-nerolidol in 
decane is ~8.76 min. RT of 
standard Z,E-FOH in decane 
(peaks (ix) and (xi)) is ~9.81 min. 
RT of standard EE-FOH in 
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Figure	  A1-­4.	  NMR	  trace	  of	  biosynthesized	  Z,E-­FOH	  	  
 
Figure	  A1-­5.	  E,E-­FOH	  calibration	  curve	  for	  the	  quantification	  of	  biosynthetic	  
Z,E-­FOH	  by	  gas	  chromatography	  
y = 78.82x - 53.68 
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